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The main physiological function of the gastrointestinal tract is to di-
gest food constituents that can subsequently be absorbed as nutrients
and at the same time provide an efﬁcient barrier to toxic materials, in-
cluding peptides, viruses and bacteria.Whether administered in soluble
form or formulated in nanoparticles, these two functions are clearly at
odds with the oral delivery of largemolecules such as peptides and pro-
teins. It is, therefore, not surprising that oral delivery of peptide drugs
remains a challenge. While, in theory, nanoparticles have a good poten-
tial to enable the oral delivery of peptides and proteins, the design of a
nanoparticle able to survive passage through the gastrointestinal tract
and to pass the intestinal epithelium is in itself a signiﬁcant challenge
[1–3].
In this contribution, we ﬁrst review current knowledge regarding
the molecular properties required for oral absorption of peptides. We
then discuss the physiological barriers to oral delivery of peptides and
nanoparticles. Examples of principles that have been used to enhance
peptide and nanoparticle delivery across each of these barriers are pro-
vided. For a comprehensive review of nanoparticle design for oral deliv-
er see [1]. Finally, we also investigate the suitability of human intestinal
tissues for studies of oral peptide and nanoparticle delivery. Important
differences as compared to commonly used cell culture models are
identiﬁed. To investigate the maximal absorbable fraction of selected
peptide delivery systems, we used a simple mechanistic computational
model for scaling in vitro and ex vivo experimental permeability data to
human in vivo intestinal permeability.
2. Peptide drugs
The number of peptide drugs in preclinical development and under-
going clinical trials has increased in recent years [4]. This is partly ex-
plained by the larger size of peptides compared to conventional drugs.
The greater size allows for interaction with targets with shallow and
or extended binding pockets that are not usually accessible to smallmo-
lecular drugs. Such targets include intracellular protein–protein interac-
tions, which are implicated in many human diseases. A requirement for
interaction with such intracellular targets is that the peptide drug can
permeate the cellular plasma membrane and reach the intracellular
compartments. In general, this does not seem to be the case, since the
vast majority of peptide drugs have extracellular targets [4]. Further,
they are administered by parenteral routes, suggesting that they cannot
permeate cellular barriers such as the epithelia underlying our mucosal
surfaces. If peptide drugs could be modiﬁed or formulated to permeate
epithelial barriers (in particular the intestinal barrier after oral adminis-
tration) and later, the plasma membranes of the target cells, tremen-
dous therapeutic advantages would result.
So what are the limits with regard to the molecular properties that
would allow for oral administration of peptide drugs? Doak et al., re-
cently investigated this issue [5]. An excellent and detailed analysis
was performed of all drugs and clinical candidates outside the rule of
ﬁve, including 226 oral drugs of various types. The authors observedthat a chemical space far beyond the rule of ﬁve allows for oral admin-
istration of (peptide) drugs. Thus, a molecular weight of up to 1000 D, a
ClogP up to 10 and a 2D polar surface area (PSA) up to 250 Å2 may still
allow for oral administration. The number of hydrogen bond donors
could, however, only be extended to 6. The 2D PSA limit of 250 Å2 is
much higher than the originally proposed 140 Å2 [6]. Interestingly,
this could be explained by 3D PSA analysis showing that the formation
of ﬂexible interactions, such as intramolecular hydrogen bonds and di-
pole–dipole interactions reduced the polar surface area to values
below 140 Å2.
In summary, the analysis of Doak et al., extends the chemical space
for oral peptide delivery beyond the rule of ﬁve [5]. However, it is
clear that for the many peptide drugs larger than approximately
1000 D, other approaches such as optimized delivery systems are re-
quired to enhance peptide permeation across the intestinal barriers
and the plasma membranes of the target cells. In the following, we
will review these barriers, present ways to circumvent them and then
focus on predictivemodels for the assessment of peptide delivery across
the intestinal barrier. For the sake of clarity, we use the expression pep-
tide for all peptides and proteins that require additives or delivery sys-
tems, e.g. absorption enhancers, or nanoparticles to be absorbed via
the oral route.
3. The barriers
On its way through the gastrointestinal tract, any drug will encoun-
ter a series of barriers before it reaches the capillaries in the
subepithelial tissue (Fig. 1). The main barriers are the gastric and intes-
tinal milieu, the mucus barrier, the tight junctions blocking paracellular
passage, the epithelial cells of the gastrointestinal tract, and ﬁnally the
subepithelial tissue. Here we summarize the hurdles that an orally de-
livered peptide drug must overcome before being absorbed. Examples
of interesting strategies that have been attempted to overcome the bar-
riers are presented.
3.1. The gastric and intestinal digestive environment
After oral intake, a peptide drug will encounter a series of digestive
enzymes whose purpose is to degrade macromolecules into absorbable
nutrients [7,8]. The enzymes involved in digestion of food constituents
are well studied and have been comprehensibly reviewed elsewhere
[9–11]. Data on enzyme expression levels and tissue localization can
be found in the Human Protein Atlas (www.proteinatlas.org) [12,13].
Digestive enzymes in the saliva are mixed with the oral drug already
in the mouth. The enzymes lingual lipase (EC 3.1.1.3) and amylase (EC
3.2.1.1) are secreted in the saliva and start the breakdown of fats and
sugar during mastication. The zymogens pepsinogens A (EC 3.4.23.1)
and pepsinogen C (EC 3.4.23.3) are then added to the mix in the stom-
ach and activated to the proteases pepsin A and gastricin by hydrochlo-
ric acid. Trypsinogen (EC 3.4.23.18) and chymotrypsinogen (EC
3.4.21.1) are added to the chyme with the pancreatic ﬂuids that are se-
creted into the duodenum after food intake in response to, among other
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Fig. 1. The gastrointestinal barriers to oral peptide delivery. The drawing shows the main
barriers to oral delivery of peptide drugs: the gastric and intestinal enzymes, the mucus
barrier, the tight junctions, the intestinal epithelial cells lining the gastrointestinal tract,
and the subepithelial tissue. Strategies to overcome these barriers are presented below
the graphics.
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zymogens are activated into the mature proteases trypsin (EC
3.4.21.4) and chymotrypsin (EC 3.4.21.1) by enteropeptidase (trans-
membrane protease, serine 15, TMPRSS15, EC 3.4.21.9) expressed in
the duodenal epithelium. Pancreatic lipase (PNLIP, EC 3.1.1.3), elastases
(a group of proteases, EC 3.4.21.36/70/71) and amylase are also secreted
with the pancreaticﬂuids. The presence of high concentrations of prote-
ases in the gut lumen is clearly a signiﬁcant challenge for oral peptide
delivery.A
DPP4
Jejunum
Colon
ENPEPB
Fig. 2. Expression of brush border peptidases in the human intestinal epithelium. A. Drawings
B. Immunohistochemical staining of selected peptidases is shown. Peptidases with high e
aminoopeptidase (ENPEP), membrane metallo-endopeptidase (MME), and transmembrane pr
at high levels in the jejunum, but not in the colon. The enteropeptidase TMPRSS15 is found i
the Human Protein Atlas (www.proteinatlas.org) [12,13].Bile is added to the chyme in the duodenum in response to food in-
take. Lipids stimulate the release of CKK from epithelial cells in the du-
odenum leading to gall bladder contraction and secretion of pancreatic
ﬂuid. Drug formulations or nanoparticles containing a lipid phase will
start to be digested at this stage and will be disrupted by lipase and
bile salts, respectively. It has been shown that solid lipid nanoparticles
as well as mixedmicelles are efﬁciently digested in themouse intestine
limiting the absorption of intact nanoparticles and micelles over the in-
testinal wall [3].
In addition to the luminal enzymes, the enterocytes of the small in-
testine express many digestive enzymes in the microvilli of the brush
border membrane and within the glycocalyx. Peptidases with high ex-
pression in enterocyte microvilli include, but are not limited to
dipeptidyl-peptidases 3 and 4 (DPP3, EC 3.4.14.4 and DPP4, EC
3.4.14.5), glutamyl aminoopeptidase (ENPEP, EC 3.4.11.7), membrane
metallo-endopeptidase (MME, EC 3.4.24.11), transmembrane protease
serine 4 (TMPRSS4, EC 3.4.21.-), and transmembrane protease serine
15 (TMPRSS15 EC:3.4.21.9) (Fig. 2).
Caco-2 cell monolayers (a model commonly used to predict intesti-
nal permeability) do not express themajority of these proteases. For in-
stance, TMPRSS4 and DPP4 are found in Caco-2 cells at modest
expression levels [14]. Despite the relatively weak expression in Caco-
2 cells, both DPP4 and serine dependent peptidases (such as TMPRSS4)
have been shown to digest small peptides during their permeation of a
Caco-2 cell layer, and this digestion is likely to be even more efﬁcient
in vivo [15,16]. Indeed, in Ussing chamber permeability experiments
with rat ileal and colonic tissues it was observed that the comparatively
metabolically stable vasopressin analogs lysine vasopressin and
desmopressin were enzymatically degraded to a major extent during
passage of the intestinal tissue [17]. The transit time of the small intes-
tine is rather constant and 2–4 h is the common timespan. The transit
time in the colon is much longer (up to 24 h) [18–20]. For more infor-
mation on GI transit times see [18,21]. Like other physiological parame-
ters, gastrointestinal transit times display large species differences
where rodent gastrointestinal transit times are much smaller than
human [21]. In rat, jejunal, small intestinal, and total gastrointestinalDPP4
ENPEP
TRMP
MME
TMPRSS15
D
uodenum
Jejunum
MME
of intestinal epithelial cells with microvilli that express many peptide degrading enzymes.
xpression in enterocyte microvilli include dipeptidyl-peptidases 3 (DPP3), glutamyl
otease serine 15 (TMPRSS15). DPP3, ENPEP, and MME brush border peptidases are found
n the duodenum but not in the jejunum. The immunostained sections are adapted from
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[22–24]. Regardless of species a peptide drug that is poorly absorbed
is exposed to peptide degrading enzymes for a signiﬁcant amount of
time.
Experience from conventional formulations shows that the peptide
degrading acidic environment in the stomach can be avoided by enteric
coated formulations [25,26]. Loading of the peptides into a nanoparticle
can provide protection during the passage of the gastrointestinal tract
allowing delivery of the peptides to or near the enterocytes of the intes-
tinalwall. Conjugationof peptideswith, e.g. lipids into lipopeptides [27],
can also protect peptides from degradation, as can the addition of en-
zyme inhibitors [17]. In the latter case, dilution of the inhibitor in the lu-
minal contents upon releasemay be a problem. It is noteworthy that the
few orally administered peptides on the market (cyclosporin A and
desmopressin) or under new drug application (NDA) review by the
US Food and Drug Administration (FDA) (octreotide) are cyclic pep-
tides, more speciﬁcally macrocycles [25]. Macrocycles stabilize peptides
against enzymatic degradation, and the stabilizing effect of cyclization
has been exploited to develop cyclic peptide prodrugs [16].
3.2. The mucus barrier
3.2.1. Mucus barrier structure
The ﬁrst physical barrier to absorption in the gastrointestinal tract is
the mucus barrier, a hydrogel layer composed of large glycoproteins,
predominantly of the mucin family [28–31]. In the small intestine
MUC2 is the main mucin secreted from goblet cells, while these cells
also secrete MUC5B in the colon (Fig. 3) [28,32–34]. Mucus production
amounts to an average of 1 kg/day in an adult human. The mucus
layer in the human intestine ranges from 10 to 100–200 μm thick (jeju-
num to colon) and consists of an outer, loosely adherent layer, and an
inner, thinner, and more strongly adherent layer. The inner, stronglyA
Jejunum
Colon
MUC4 MUC5BB
GE
Fig. 3.Expression ofmucins in thehuman intestine. A. Drawings of intestinal enterocytes (E) and
extracellular mucus barrier are shown. Parallel sheets of secreted mucins cover the villi of the s
(MUC2) bind to three other mucin proteins, creating a hexagonalmesh. In the jejunumMucin-2
well. The structure of Mucin-5B containing mucus has not been determined. B. Expression of s
goblet cells. Mucin-5B (MUC5B) is found in the colon only. Mucin-13 (MUC13) is found in th
also part of the glycocalyx, shows higher expression in the jejunum than in the colon. The imm
[12,13].adherent layer has been estimated to be 7 μm thick in the colon, but
its thickness has not to our knowledge been determined in the human
small intestine [35,36]. The outer loosely attached layer is thin in the
small intestine (10 μm) but thicker in the colon (40–100 μm) [28,
35–37]. The mucus barrier shows large species variations, with the rat
intestinal mucus layer being tenfold thicker or more in all segments of
the intestine compared to the thickness in humans [36–38]. Both
mucus layers consist of stacked, parallel sheets of mucinmolecules cov-
ering the intestinal surface on top of and between the villi in the small
intestine [34,39]. Some structural features of mucus have been identi-
ﬁed. In mucin-2 (MUC2) based mucin-sheets each mucin-2 protein
binds to three neighbors, creating a hexagonal mesh [29,34,40].
Closest to the epithelium is the 0.5 μmthick glycocalyx, comprised of
polysaccharides bound to membrane anchored mucin proteins, MUC 1,
3, 12, 13 and 17 in the human jejunum and colon [12,32,41] (Fig. 3). In
both tissues, MUC13 and 17 seem to exhibit the strongest expression. In
addition, the glycocalyx of the goblet cells contains MUC4 that is exclu-
sively expressed by these cells [12,42]. Using transmission electron mi-
croscopy, it has been shown that the glycocalyx is pronounced over
enterocytes, but of much lesser thickness over microfold cells, M-cells
which are epithelial cells covering the lymphoid follicles in the intestine
[43,44]. In addition to mucins, the mucus layers also contain large
amounts of enzymes with the capacity to break down sugars, lipids
and proteins to provide digested nutrients for absorption by the
enterocytes (see Section 3.1). These enzymes pose a risk of digestion
for peptide drugs entering the mucus layer.
The role of the mucus layer is to lubricate the passage of chyme, to
protect the epithelium frommechanical damage and to bind pathogens
and hinder them from reaching the epithelial cells [28]. The small intes-
tine is a rather sterile environment, but in the colon, gut ﬂora typically
resides in the outer mucus layer down to the surface of the inner,
strongly attached mucus layer [35,38]. While the glycocalyx restrictsMUC13
MUC17
MUC2 MUC2
MUC13 MUC17
MUC2 MUC2
MUC2 MUC2 MUC2 MUC2 MUC2
goblet cells (G).Mucins of theglycocalyx andmucins secretedby goblet cells that form the
mall intestine. The sheets are made up of mucin aggregates, in the jejunum each Mucin-2
(MUC2) is themajor secretedmucinwhile in the colonMucin-5B (MUC5B) is secreted as
elected mucins in the jejunum and colon. Mucin-4 (MUC4) staining is seen exclusively in
e glycocalyx of the enterocytes in both jejunum and colon. Mucin-17 (MUC17), which is
unostained sections are adapted from the Human Protein Atlas (www.proteinatlas.org)
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villus epithelium, the thin glycocalyx over M-cells of the lymphoid folli-
cles presents a weaker barrier [43,44].
Caco-2 cells are a common model of the human intestinal epitheli-
um, but a drawback associated with this cell model is that they lack a
mucus layer. Caco-2 cells only express detectable levels of the glycoca-
lyx mucins MUC13 and MUC 17 [14]. Further, as for M-cells, the glyco-
calyx of Caco-2 cells is thinner than in normal enterocytes, which is
probably related to their tumor origin [45]. Frey et al., concluded that
a comparably good uptake of gold nanoparticles by Caco-2 cells com-
pared to that in intestinal tissues might be due to this thin glycocalyx
[44]. This is supported by the observation that intestinal epithelial M-
cells in lymphoid follicles, that have the capacity to transcytose nano-
particles, have a less pronounced glycocalyx [43]. Goblet cell clones iso-
lated from the colonic epithelial cell line HT-29 cells secreteMUC 2, 5AC
(normally found in the stomach, but not in the intestines), and colonic
MUC 5B, and, additionally, show weak expression of MUC 1, 3 and 4
[46–48].
3.2.2. Mucus interactions
The mucus binds nanoparticles and proteins via hydrophobic inter-
actions [49]. Charged groups of the mucin proteins can also interact
with charged particles and immobilize them in the mucus [50]. The
charge density in the mucus mesh will depend on local ionic strength
and pH, and will thus be inﬂuenced by the chyme content in the intes-
tine. The ionic strength, ionic composition, and pH have all been shown
to vary signiﬁcantly depending on the location in the intestine, feeding
status and meal contents. Osmolality and ionic strength can ﬂuctuate
from hypotonic to isotonic to hypertonic within short distances in the
gut after a meal [51]. Under hypertonic conditions, charge interactions
between mucus and particles will be partially shielded by ions in the
ﬂuid, reducing interactions below the levels seen in hypotonic ﬂuids
[50]. Particle interactions with the mucus will depend partially on,
among other factors, feeding state. It has recently been demonstrated
that postprandial levels of calcium, bile acids and lipids lead to a denser
and more impenetrable mucus, presumably by inﬂuencing interactions
between mucin molecules affecting mucin–mucin binding and mucus
mesh architecture [52]. In addition, dietary and pharmaceutical poly-
mers such as pectin and PEG can compress mouse colonic mucosa by
up to 80%, tightening the mucus structure [53].
Immobilization of peptides, particles or pathogens in the outer
loosely adherentmucus layerwill lead to rapid clearing from the gastro-
intestinal tract as this mucus layer is shed. Small solutes, such as nutri-
ents do, however, diffuse unimpeded through the mucus layer [35]. It
has been shown that densely charged but overall neutral hydrophilic
particle surfaces exhibit limited interactions with mucus [54]. Indeed,
for many virus capsids, the diffusion rate through native cervical
mucus approaches the diffusion rate in phosphate buffered saline solu-
tion (PBS) [54,55]. Olmsted et al., showed that for particles with densely
charged, net neutral, hydrophilic surfaces, themucusmesh sizewas ap-
proximately 100 nm [54].
Building on these ﬁndings, mucus penetrating particles (MPP) were
developed [56,57]. By decorating the surface of nanoparticles with a
dense layer of lowmolecular weight PEG-chains, particles were created
with weak mucus interactions that are capable of rapid diffusion
through the cervical mucus layer. When the density of PEG-chains
was decreased, the particles were trapped in the mucus layer. Further,
nanoparticles covered with longer PEG-chains did not penetrate the
mucus layer, probably due to entanglement between the longer PEG-
chains and the mucus mesh. The MPPs were found adjacent to the epi-
thelial cell layer while conventional nanoparticles were immobilized in
the outer regions of the mucus layer [57]. Many soluble proteins also
display a hydrophilic surface, leading to limited interactions with
mucus proteins. Nanoparticles covered with serum albumin exhibit
weak, repulsivemucus interactions due to the negative charge of the al-
bumin protein [58]. In theory, nanoparticle binding to the mucussurface layer might be a viable strategy for the delivery of small mole-
cules and stable peptides allowing concentrated, controlled release of
the peptide in the vicinity of the enterocyte. In practice, the loosely at-
tached outermucus layer and peptidases of the intestinewill be a signif-
icant barrier to this approach. MPPs are therefore an attractive strategy,
but their value after oral administration in humans remains to be
proven.
The densely charged, hydrophilic surface of MPPs is detrimental to
membrane permeation and entry into the epithelial cell. To address
this problem, a multifunctional MPP was developed that ﬁrst shed its
outer mucin-penetrating shell as it passed the mucus layer [59]. Shed-
ding of the shell exposed the inner core structure of the nanoparticle
composed of a complex of the cell penetrating peptide (CPP) penetratin
and insulin. This construct led to a 60% blood glucose lowering in rats
after administration of a comparably high dose of 75 IU/kg. While this
construct demonstrated proof of concept, its advancedmulticomponent
structure might make it impractical for clinical investigation.3.3. Tight junctions
3.3.1. Tight junction structure and function
Tight junctions are seals between adjacent epithelial cells restricting
paracellular ﬂux of water, ions and solutes [60,61]. The tight junctions
are localized in a ring towards the apical pole of the cell. The junctional
strands separate the basolateral and apical membranes of the epithelial
cells and are instrumental in maintaining epithelial and endothelial tis-
sue barriers as well as cell polarity.
The junctions are composed of branching strands which are them-
selves composed of rows of transmembrane proteins with extracellular
domains, predominantly of the 27-member claudin (CLDN) family and
occludin (OCLN) [62,63]. The extracellular domains of these proteins
form loops that bind to the corresponding loops of adjacent cells, creat-
ing a seal between the two cells [64,65]. At the junctions between three
adjacent cells, a third protein, tricellulin (MARVELD2), forms a junction
[60,61]. Claudins are found in various combinations in different tissues
and there is strong evidence that these proteins are responsible for
the paracellular barrier functions in various tissues, including the intes-
tine [62,63]. The intracellular domains of the claudins are linked to pe-
ripheral scaffolding proteins such as ZO-1 (zonula occludens 1). ZO-1
is in turn connected to cytoskeleton components such as actin, myosin,
and microtubules via linker proteins. Phosphorylation of several of
these intracellular proteins affects the junctional complex and hence
regulates the tightness of the paracellular barrier, a feature that has
been exploited to enhance the delivery of peptides (see Section 3.3.2.
below) [66,67].
Claudins are classiﬁed into two groups— barrier-forming and pore-
forming, the latter controlling the selective passage of small solutes over
the epithelium [63]. Of the claudins present in the jejunum, claudin-2
and claudin-15 (CLDN2 and CLDN15) are considered pore-forming
(Fig. 4) [68]. Claudin-2 pores allow permeation of Na+, some other cat-
ions, and H2O; while Claudin-15 pores are permeable to Na+, K+, Li+,
but not Cl−. The Na+ leak through the tight junction pores is required
for normal function of sodium-dependent nutrient uptake such as
glucose and amino acids via transport proteins, e.g. the sodium-
dependent glucose transporter 1 (SGLT1, SLC5A1) [69]. When
Claudin-15 is knocked out in mice, the intestinal lumen is quickly de-
pleted of Na+, impeding glucose absorption [69]. The opening of the
Na+ pathway is induced by SLC5A1-mediated glucose uptake in a pro-
cess involving activation of myosin light chain kinase (MLCK), phos-
phorylation of myosin light chains (MLC), and a controlled tightening
of the perijunctional actin-myosin ring resulting in an increased perme-
ability of sodium and small solutes through the tight junction [61]. It is
noteworthy that this post-prandial opening of tight junctions is com-
pensated by the food induced strengthening of the mucus barrier
discussed in Section 3.2.1 [52].
Cldn
ZO-1
Cingulin
Actin
Claudin-3 Claudin-5 TricellulinOccludin
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Fig. 4. Expression of tight junction proteins in human intestinal tissues. A. Drawings of intestinal epithelial cells, the location and organization of tight junctions proteins connecting the
tight junctions with the perijunctional actin ring are shown. B. Expression of selected tight junction proteins in the jejunum and colon. Claudin-3 (CLDN3), claudin-5 (CLDN5), and
Occludin (OCLN) show intense basolateral staining in both jejunal and colonic epithelia. Tricellulin (MARVELD2), which is normally restricted to tricellular junctions, is stained on the
apical side of the cells. The more wide-spread staining than expected of the tissue section could be a result of varying tissue quality and overstaining. The immunostained sections are
adapted from the Human Protein Atlas (www.proteinatlas.org) [12,13].
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by food constituents, at least under in vitro conditions. For instance,
naringenin, a compound found at high concentration in grape fruit
juice and to a lesser extent in other citrus fruits has been shown to in-
crease the expression of claudin-1 and 4 and to tighten the junctions
in Caco-2 cells [70]. The pore pathway can also be regulated by cyto-
kines [71]. For example IL-13 leads to increased transcription of
claudin-2 [71]. Stronger inﬂammatory stimuli such as TNF-α can lead
to a stronger tightening of the actin-myosin ring leading to the opening
of a leak pathway allowing permeation of larger solutes, even macro-
molecules [72–74]. This leak pathway is also associated with occludin
internalization and a general weakening of the tight junction barrier
[72,75]. The leak pathway is involved in diarrhea after bacterial infec-
tions in the gut and may be too difﬁcult to control to be of interest for
enhanced peptide delivery [61,72].
The individual claudin concentration and composition of the tight
junctions differs along the intestine. This is reﬂected in permeability
studies, using hydrophilic paracellular marker molecules, whose per-
meabilities decrease from the small intestine to the colon. The human
protein atlas combined with proteomic studies, and other expression
studies show that claudins 1, 2, 3, 4, 5, and 15 are expressed in the
human jejunum, while claudins 1, 3, 4, 7, 8, 12, and 15 are found in
the human colon, and Caco-2 cells, ﬁnally express claudins 1, 2, 3, 4,
15, and 17 (Fig. 4) [12,14,32,76–78]. The notable absence of claudin-5
in Caco-2 cells distinguishes it from human jejunum, while the absence
of claudin-8 is a deviation from the colon phenotype.
Interestingly, selective suppression of claudin-5 regulates the per-
meability of the blood–brain-barrier in mice and was applied to reduce
brain oedema after acute brain injury [79]. Since claudin-5 is expressed
in human jejunum, it could be tempting to investigate this mechanism
in Caco-2 cells with the aim of improving peptide delivery. Such an in-
vestigation would be meaningless, however, owing to the lack of
claudin-5 in these cells. This hypothetical example underscores the im-
portance of prior knowledge of the differences between cellularmodelsand primary human tissues before initiating functional studies. Previ-
ously, such information has been difﬁcult to obtain, but global omics
data are now rapidly becoming generally available [14,32]. This will be
very helpful in understanding old and discovering new mechanisms of
tight junction regulation for enhanced peptide delivery.
3.3.2. Tight junction modulation for oral peptide delivery
Modulation of tight junction permeability has often been attempted as
ameans for peptides or nanoparticles to cross the epithelium. To this end,
two types of strategies have been adopted, a seemingly less controlled
tight junction modulation, creating leaks that allow the passage of large
molecules, and amore controlled tight junctionmodulation. In the former
case, surface active so-called absorptionenhancers havebeenused. Famil-
iar examples are medium chain fatty acids and their derivatives. While
these agents cause reversible leaks in tight junctions within narrow con-
centration intervals in vitro, these levels are difﬁcult tomaintain after oral
or local administration in vivo [25,80–82]. At higher concentrations,many
of the surface active enhancers also interactwith cellmembranes, causing
irreversible damage to the intestinal epithelium. Notably, the less surface
active shortermedium chain fatty acid sodium caprylic acid (C8) is added
in an oral formulation of the macrocyclic peptide drug Octreotide, which
is under NDA review by the US FDA [25].
A better controlled tight junctionmodulation seems to be amore at-
tractive way than permeation enhancers to increase paracellular pep-
tide permeability. As indicated above, myosin light chains (MLC) are
connected to the peripheral scaffold proteins of the tight junctions.
MLC are phosphorylated by myosin light chain kinase (MLCK) which
leads to tight junction opening [61,67]. This opening is then reversed
by dephosphorylation catalyzed by myosin light chain phosphatase
(MLCP) (Fig. 5) [83]. In contrast to the strong effect on the leak pathway
created by TNF-α, or certain absorption enhancers when used at high
concentrations, myosin phosphorylation via MLCK seems to be more
controllable and leads to tight junction opening without occludin inter-
nalization [84,85]. To exploit this ﬁnding, several MLCP inhibitory
MLC
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Fig. 5. Tight junction modulation. A. Schematic drawing of tight junction modulation redrawn from [66]. Phosphorylation of myosin light chains (MLC) by myosin light chain kinase
(MLCK) leads to contraction of the actin-myosin ring and tight junction opening. MLC-P dephosphorylation by MLC phosphatase (MLCP) reverses the process. Inhibition of MLCP tilts
the balance towards tight junction opening. B. Electron micrograph of a Caco-2 epithelial tight junction connected to the actin-myosin perijunctional ring (×11000).
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and kinetics of tight junction modulation were identiﬁed. Injections of
these different peptides together with 30 IU/kg insulin into the intesti-
nal lumen in rats resulted in a signiﬁcant lowering of the blood glucose
in the range of 30–50%. In untreated animals,ﬂuorescently labeled insu-
lin could be visualized along the epithelial brush border, and after treat-
ment with MLCP inhibitory peptides, the labeled insulin could be seen
penetrating between enterocytes and into the subepithelial tissue. It
was calculated that the most efﬁcient MLCP inhibitory peptide led to
an insulin bioavailability of 3–4%, demonstrating that tight junction
modulation is a promising strategy for intestinal peptide delivery. Rath-
er high concentrations of the peptides and also of insulin were required
for effective modulation and it remains to be shown if this approach
holds promise when scaled up to larger species. It is also likely that
the pathway opened by controlled tight junctionmodulation is too nar-
row to allow passage of nanoparticles.
3.4. Intestinal epithelial cells
Intestinal epithelia of the small intestine and colon present a large
absorptive surface that mainly consists of absorptive enterocytes and,
to a lesser extent, of mucus secreting goblet cells. From studies in ro-
dents, the fraction abundance of goblet cells has been estimated at
10–20%, increasing towards the colon [86,87]. Less than 1% of the epi-
thelial cells are enteroendocrine cells secreting hormones such as
Glucagon-like peptide-1, GLP-1, in response to stimuli in the intestinal
lumen [88,89]. Dendritic cells of the immune system are also found
within the epithelium, but they are scarce [90]. Microfold cells, M-
cells, are a rare type of epithelial cell found in lymphoid follicles in the
intestinal tract [91]. Larger follicles and surrounding tissue are refered
to as Peyer's patches. M-cells have received much attention as a poten-
tial route of nanoparticle or peptide delivery as a result of their compar-
atively high rate of transcytosis [92,93]. Most of these studies have been
performed in rodents. The prevalence of M-cells is much lower in man
and estimates of M-cell nanoparticle uptake in rodents may, therefore,
not translate to humans [94].
The total length of the human small intestine is 6–7 m, 2.5 m of
which belongs to the jejunum. The internal surface of the jejunum is
very large and convoluted. This is the result of large transversal folds,
the folds of Kerckring, and the villi, 1 mm long, ﬁngerlike or leaf-like
projections covering the intestinal epithelium. Villi are longer and
more densely spaced in the jejunum than in other parts of the small in-
testine. The apical membrane of the absorptive enterocytes is covered
by densely packed microvilli, further amplifying the surface area of
the intestine. The total surface area of the small intestine is commonlyestimated to be 250–300 m2, although recent studies suggest that the
area is smaller, approximately 30 m2 [95,96]. The discrepancy is caused
by the problems inherent in determining the length, diameter, and fold-
ing of the small intestine that varies with the tonus of the underlying
muscle layers. Measurements post mortem and in living subjects
show large differences, making area estimates uncertain. The surface
of the colonic mucosa is much smaller, due to the lack of villi, and is
commonly estimated at 1–2 m2 [96]. Fig. 6 shows the appearance of in-
testinal villi and microvilli of absorptive cells.
Small lipophilic peptides can, depending on molecular properties,
distribute into the phospholipid bilayer and thus pass an epithelial cell
by simple diffusion [5]. As indicated in Section 2, peptide drugs are,
with some exceptions, generally too large and polar to penetrate the
cell membrane. Peptide transporters such as peptide transporter 1
(PEPT1, SLC15A1) show a large capacity for the transport of di- and
tripeptides, but most peptide drugs are much larger [97,98]. Transport
proteins suitable for the delivery of large peptide drugs have not been
identiﬁed in the plasma membranes of intestinal epithelial cells. Alter-
native routes across the cell membrane(s) must, therefore, be targeted.
3.4.1. Cell penetrating peptides
One such route is exploited by so-called cell penetrating peptides
(CPPs), of which the ﬁrst discovered was the trans-activating transcrip-
tional activator (TAT) from human immunodeﬁciency virus 1 [99]. CPPs
are a heterogeneous collection of cationic or amphipathic peptides of 5–
30 amino acid lengths. They are derived from natural proteins (e.g.
penetratin) or artiﬁcial sequences (e.g. octarginin) that have the ability
to disrupt and penetrate the plasma and/or endosomalmembrane [100,
101].
There are about 1000 CPPs that may enter cells by means of a num-
ber of differentmechanisms and that express awide variety of toxicities
[100,102]. This complexity has slowed down the application of CPPs for
peptide delivery. CPPs with the ability to deliver cargo (e.g. therapeutic
peptides) often enter the cell through endocytosis and subsequent lysis
of the endosomal membrane [103]. Thus, a CPP-delivered therapeutic
peptide will encounter additional proteolytic activity in the endosomes.
CPPs have, therefore, been combined with nanoparticle encapsulated
cargo. Apart from protecting the peptide, this approach has the addi-
tional theoretical advantage of keeping the CPPs sufﬁciently concentrat-
ed to facilitate the exit from the cell into the subcellular tissue.
Cell penetrating peptides have been incorporated into nanoparticles
with promising results. A mucus penetrating nanoparticle with a CPP
core was discussed in Section 3.2.2 [59]. Another nanoparticle strategy
combined a CPP (penetratin) with a secretion peptide, Sec, derived
from the secreted transcription factor, Engrailed, on the surface of
C5 um
10 um
BA V
M
Fig. 6. Villi andmicrovilli of the intestine. A. Section of jejunal tissue after stripping off submucosal tissue andmounting in an Ussing chamber. The upper edge of the specimen consists of
the villi (V) at themucosal surface. The lower limit of the specimen is delineated by themucosamuscularis (MM), on the serosal side of themucosa (Hematoxylin–Eosin stain). B. Scanning
electron micrograph of the microvilli covered surface of Caco-2 cells (×11,000). Note the selective adherence of three spherical particles to a cell surface with low density of microvilli.
C. Transmission electron micrograph of microvilli structure on the apical surface of Caco-2 cells (×11000). Note the absence of a dense glycocalyx.
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enterocytes [104]. The Sec peptide is a signaling peptide directing the
Engrailed transcription factor to the protein export machinery in the
cell [105]. The nanoparticle decorated with both peptides was shown
to be signiﬁcantly more effective than a nanoparticle employing only
penetratin, both in in vitro permeability experiments in Caco-2 cells
and in vivo experiments. Nanoparticles decorated with penetratin
alone (size 148 nm) achieved an insulin bioavailability of 9% after ileal
administration of 10 IU/kg insulin in rat, while particles decorated
with both penetratin and the Sec peptide (size 163 nm) increased the
bioavailability of the insulin cargo to 15% [104]. However, insulin loaded
into unmodiﬁed poly (D,L-lactic-coglycolic acid) (PLGA) nanoparticles
(size 160 nm) achieved a bioavailability of 5% in the same study,
which seems inexplicably high. It remains to be determined whether
these very promising results can be replicated in independent studies.
The use of the Sec peptide to target the nanoparticle to the cells' protein
export machinery to exit the cell is a similar approach to the
transcytosis targeted delivery that will be discussed in the followings
sections.3.4.2. Endocytosis and transcytosis
The second route for peptide transport across a cellular barrier has
been to target peptides or nanoparticles to a naturally occurring
transcytosis mechanism present in the epithelial cells. Transcytosis is
a mechanism by which polarized cells transport material from one
side of the cell to the other [106]. The ﬁrst step of the transcytotic
route is endocytosis. Endocytosis is a general mechanism present in
all cells that transport membrane proteins and extracellular material
in membrane vesicles into the cell interior [107]. The mechanisms ofendocytosis have been relatively well studied (Fig. 7A). In contrast,
the mechanisms of transcytosis are not as well understood.
Transcytosis across epithelia is mediated by speciﬁc mechanisms
and is a rather rare event. Examples of transcytotic mechanisms, some
of which have been exploited for peptide and nanoparticle delivery
are given in Table 1.
Endocytosis is classically divided into four separate mechanisms,
clathrin-mediated endocytosis, caveolae, macropinocytosis and phago-
cytosis.Many studies show that in addition to these pathways a number
of clathrin- and caveolin-independent mechanisms exist (reviewed in
[107,127]). Clathrin- as well as caveolin-dependent endocytosis in-
volves receptor binding ofmacromolecules and subsequent internaliza-
tion. Typically, in neither of these cases, do the endocytotic vesicles
exceed 150 nm in diameter, but exceptions occur [128–130].
Macropinocytosis internalizes small droplets of liquid and solutes
from the extracellular ﬂuids [131]. The diameter of endocytotic vesicles
resulting from macropinocytosis can be larger than those from clathrin
and caveolin-mediated endocytosis. Phagocytosis involves the internal-
ization of larger particles and pathogens [107]. All of these four endocy-
tosis mechanisms are dependent on dynamin motor proteins that split
the endocytosed vesicle from the plasma membrane [132,133]. It has
been proposed that all four of the classic endocytosis mechanisms are
involved in nanoparticle uptake in epithelia [134,135].
Caco-2 cells display comparatively low endocytotic activity com-
pared to intestinal epithelia and also lack detectable expression of
caveolins using high resolution mass spectrometry [14]. However,
caveolins have been detected in differentiated Caco-2 cells by western
blotting [136]. To enhance endocytotic activity in the in vitro model a
co-culture system has been devised that induces an M-cell like pheno-
type in the Caco-2 cells (see Sections 3.4.4 and 4) [137,138].
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Fig. 7. Expression of dynamin and of Rab GTPases in human intestinal tissues. A. Drawings of intestinal epithelial cells showing RAB-proﬁles of endosomes and organelles involved in
endocytosis and transcytosis. Known and hypothesized (marked by ?) pathways of endocytosis and transcytosis are illustrated. AEE, apical early endosome; ARE, apical recycling
endosome; BEE, basolateral early endosome; CRE, common recycling endosome; LE, late endosome; and LY, lysosome. B. Expression of selected proteins involved in endocytosis and
transcytosis in the intestinal epithelium. Dynamin-2 is highly expressed in jejunal and colonic epithelia. The Rab interacting protein Rab11FIP5 has been implicated in transcytosis.
Rab11FIP5 displays punctate staining below both the apical and basolateral membranes, expression levels being higher in the jejunum than in the colon. RAB17 and RAB25, both of
which have been associated with the transcytotic process are expressed in both jejunal and colonic epithelia. The immunostained sections are adapted from the Human Protein Atlas
(www.proteinatlas.org) [12,13].
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endocytosis is the lack of speciﬁc inhibitors. Therefore a general inhibi-
tor of dynamin-mediated vesicular internalization, such as dynasore,
that inhibits all the classical endocytosis pathways is typically used
[139,140]. For speciﬁc pathways chlorpromazine is considered a selec-
tive inhibitor of clathrin-mediated endocytosis, while ﬁlipin inhibits
caveolin-mediated endocytosis [141,142]. For macropinocytosis, no se-
lective inhibitors have been identiﬁed [141].
Rab GTPases control endosome trafﬁcking in eukaryotic cells [143].
Expression of more than 50 different Rab isoforms has been detected
at the protein level in the intestinal epithelium [32]. Many Rab isoforms
are speciﬁc for particular organelles and endosomes. Co-localization
studies using Rab isoform speciﬁc antibodies have been used to track
endocytosed and transcytosed materials. Rab GTPases act as molecular
switches; their function in vesicular transport has been comprehensibly
reviewed elsewhere [143,144]. Below, RAB involvement in endocytotic
and transcytotic pathways is brieﬂy discussed.
After budding of the endocytotic vesicle from the apical cytoplasmic
membrane, vesicles from all endocytotic mechanisms are internalized
into a common pool of apical early endosomes (AEE) positive for,Table 1
Examples of transcytosis mechanisms in intestinal epithelia. A subset of the transcytosed entit
Class Transcytosed entity Ligand
Receptors Neonatal Fc receptor (FcRn, FCGRT) IgG
Polymeric immunoglobulin receptor (PIGR) pIgA
Lactoferrin receptor (ITLN-1) Lactof
Vitamin B12 – intrinsic factor receptor (CUBN, AMN) Vitam
Transporters GLUT2 (SLC2A2) –
Bacterial toxins Some cholera toxins –
Shiga toxin –
Lipids Sphingolipids –
Ceramides –
Other membrane proteins Lectins –RAB4, RAB5, RAB15, and RAB22. A fraction of internalized membrane
proteins are recycled to the membrane from these endosomes. RAB22
is involved in vesicle transport between AEE, the trans-Golgi network
and the Golgi apparatus suggesting that this protein might play a role
in transcytosis (see below) [145]. A subset of internalized material is
transported further into RAB11, RAB17, and RAB25-positive apical
recycling endosomes (ARE) and a portion is recycled back to its original
membrane domain. RAB11, RAB17, and RAB25 are closely linked to the
process of transcytosis, suggesting that the recycling endosome plays a
central role in this process (see below) [146,147]. In polarized epithelia,
separate pools of early and recycling endosomes are thought to exist be-
neath the apical and basolateral membranes [148]. Basolateral early
endosomes (BEE) are distinct from their apical counterparts in their ex-
pression of RAB21. Material in the ARE that is not recycled is generally
transported into RAB7- and RAB9-positive late endosomes (LE) and
from there to the RAB7 positive lysosome (LY). In the LE, the route to
the lysosome has probably been set, and the option of transcytosis is
no longer available [143]. Thus, the common pathways of endocytosis
end either in themembrane of origin or in the proteolytic environment
of the lysosome. Studies of nanoparticle transport in epithelial MDCKies have been used for targeted peptide or nanoparticle delivery.
Utilized for peptide delivery Utilized for nanoparticle delivery Reference
Yes Yes [108,109]
No No [110]
errin Yes Yes [111,112]
in B12 Yes Yes [113–116]
No No [117]
Yes No [118,119]
Yes No [120–122]
Yes No
Yes Yes [123,124]
Yes Yes [125,126]
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transported into RAB7 and RAB9 positive compartments [149]. These
compartments are likely to be late endosomes and lysosomes. A
minority of nanoparticles were located in RAB11 positive recycling
endosomes that might have led to transcytosis [150]. Fig. 7 shows ex-
amples of Rab GTPase expression in the small and large intestine.
The mechanism giving rise to transcytosis is poorly understood. The
process shows an inherent polarity with mechanistic differences be-
tween apical to basolateral and basolateral to apical transcytosis [151,
152]. This section focuses on apical to basolateral transcytosis. It is
clear that RAB11A, RAB17 and RAB25 are involved in transcytotic trans-
port, implicating that there is a role for apical and basolateral recycling
endosomes [144,146,147]. The mechanism of endosome transfer
between apical and basolateral domains remains unidentiﬁed. It has
also been shown that transcytosis inMDCKcells is inhibited by Brefeldin
A (BfA), an inhibitor of protein and vesicle transport from the
endoplasmatic reticulum (ER) to golgi apparatus, suggesting that
these organelles play a role in transcytosis [153–155]. One intracellular
target for BfA has been proposed to be Golgi-speciﬁc Brefeldin A-
resistance guanine nucleotide exchange factor 1 (GBF1), a guanine nu-
cleotide exchange factor involved in the formation of transport vesicles
in the Golgi [156–158]. GBF1 is also involved in vesicle transport along
the retrograde pathway from apical recycling endosomes, via the
trans-Golgi and Golgi networks to the ER and BfA accordingly strongly
modiﬁes this pathway [159–162]. The retrograde pathway is used by
several polypeptide bacterial toxins to escape degradation in the lyso-
some and exert their toxic effect by escaping from the ER to the cyto-
plasm using specialized CPPs [162–164].
Interestingly RAB11 has also been shown to be involved in targeting
of endosome transport from the apical recycling endosomes to the
trans-Golgi network which suggests that the retrograde pathwayA
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proteinatlas.org) [12,13].between these organelles is a central step in the mechanism(s) of
transcytosis [165,166]. Activation by mitogen activated protein kinase
(MAPK) dependent phosphorylation of the Rab-binding protein
RAB11FIP5 leads to increased transcytosis in MDCK cells [166]. These
proteins are expressed in jejunal and colonic epithelia and at lower
levels in Caco-2 cells [12,14,32]. RAB11FIP5 shows distinctively higher
expression levels in jejunal than in colonic epithelium. In both tissues,
the protein shows a distinct subcellular localization (Fig. 7B). The pro-
tein is found in punctate stains close to both apical and basolateral
membranes that could be identical to recycling endosomes.
3.4.3. Targeting to transcytosed receptors
An example of a protein transcytosed across the intestinal epitheli-
um is IgG, which is transported from the gut lumen via the neonatal
Fc receptor (FcRn, FCGRT) [167,168]. In humans “neonatal Fc receptor”
is a misnomer as the receptor is expressed in the intestinal epithelium
throughout life. In rodents the receptor expression declines rapidly
after weaning. In neonatal rats FCGRT is highly expressed in the jejunal
epithelium where it imports milk derived IgG from the gut lumen back
into the circulation. In the slightly acidic microclimate (pH 6.5) created
by the proton gradient in the jejunal mucus layer, the FCGRT binds the
Fc-portion of IgG with high afﬁnity [169]. The receptor is then
transcytosedwith the assistance of a unique sortingmotif [170], and re-
leases its bound antibody at the neutral pH of the subepithelial tissue
(Fig. 8A). The transcytosis of FCGRT has been studied in considerable de-
tail in the neonatal rat small intestine [152]. The translocation of the re-
ceptor from the apical to the basolateral pole of the enterocyte was
found to take place in a RAB5, RAB9 and RAB11 positive endosome,
adding to the complexity of the transcytotic process. RAB9, like
RAB11, is known to be involved in endosome trafﬁcking to and from
the trans-Golgi network [143,144]. It has been proposed that the2 
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s better understood than the process of IgG secretion via FCGRT. B. Expression of selected
xpressed in jejunal and to a lesser extent in colonic epithelia. The polymeric IgA receptor
crypts. The transferrin receptor (TFRC) shows a strongly polarized expression in the
et cells. The immunostained sections are adapted from the Human Protein Atlas (www.
266 P. Lundquist, P. Artursson / Advanced Drug Delivery Reviews 106 (2016) 256–276pathway via FcRn contributes to the monitoring of the gut lumen con-
tents by the immune system, and that it might be involved in both de-
fense against pathogens and in induction of tolerance to food antigens
[167,171,172].
Few human studies of peptide delivery via transcytosed receptors
have been performed, examples in the reviewwill therefore by necessi-
ty derive from in vitro experiments and small animal species.
Perhaps the most successful use of receptor-mediated transcytosis
for peptide delivery has been via the FCGRT [109]. Pridgen and co-
workers decorated insulin loaded nanoparticles (mean diameter
57 nm)with IgG Fc-regions. This resulted in efﬁcient oral delivery of in-
sulin to wild-type mice, with a reduction of blood glucose of 45% in the
mice after oral insulin administration of 1.1 IU/kg. In contrast, knock-out
mice negative for FCGRT showed no reduction in blood glucose after
oral administration of insulin loaded Fc-nanoparticles, demonstrating
the speciﬁcity of the uptake mechanism. Importantly, the administered
dose was much lower than in previous examples, involving tight junc-
tion manipulation and CCPs, respectively and corresponds to a normal,
daily, human subcutaneously injected dose. This suggests that the bio-
availability of the orally administered insulin must be comparably
high. It will be interesting to see whether these promising results can
be reproduced in larger animal species. Fc-decorated nanoparticles or
Fc-fusion proteins have also been found to cross the lung epithelium
in vitro as well as in vivo in non-human primates and humans
[173–175].
Another example of receptor-mediated transcytosis is the uptake of
vitamin B12 by intestinal enterocytes. The process is illustrated in
Fig. 8A. Vitamin B12 is taken up as a complex with the intrinsic factor
protein (IF) in the ileum. After binding of the Vitamin B12 – IF complex
to the Vitamin B12 – intrinsic factor receptor (CUBN, AMN), the receptor
and ligand are endocytosed. The receptor is recycled to the membrane
while the Vitamin B12 – IF complex is routed to the lysosome. Here IF
is broken down and vitamin B12 is eventually released into the portal
circulation, where it is bound and transported by the transcobalamin
II protein [114,176,177]. The uptake of vitamin B12 is quite inefﬁcient,
and from a 5–50 μg oral dose about 1.5 μg is absorbed, possibly indicat-
ing saturation of the transport mechanism [178,179].
The vitamin B12 pathway has been explored for peptide delivery in
rats. In a targeted peptide delivery study, the appetite suppressing pep-
tide hPYY(3–36) was fused with vitamin B12 and after administration
by oral gavage to rats, achieved a bioavailability of 25% [113]. In other
studies, several vitamin B12 decorated insulin loaded nanoparticles
were constructed, leading to oral bioavailabilities of insulin in the 5–
26% range in rat (nanoparticle mean diameters of 125–370 nm) [115,
116,180]. It is interesting to note, and perhaps of concern, that, depend-
ing on the dose, a comparable or higher bioavailability was obtained
with each of the vitamin B12-decorated peptide delivery systems in
the small animal species than with the natural ligand vitamin B12 in
man.
Another, less obvious receptor that may be targeted for transcytosis
across enterocytes is the lactoferrin receptor (ITLN-1) thatmediates the
intestinal uptake of lactoferrin [181,182]. ITLN-1 is highly expressed in
the jejunum and colon and can be found in modest levels in Caco-2
cells [12,14,32,181,183]. The lactoferrin receptor has been used for
oral delivery of lactoferrin for T cell dependent tumor inhibition and
for oral delivery of lactoferrin loaded nanoparticles in breast cancer
treatment; both studies were conducted in mice [111,112].
Targeting oral peptide or nanoparticle delivery to a transcytosed re-
ceptor poses the risk that binding of the targeted peptide or nanoparti-
cle can be outcompeted by the physiological ligand if the latter is
present in high levels in the gut lumen. Conversely, an essential natural
ligand present at low concentrations can be outcompeted by a delivery
system when this is given in high amounts. One way to avoid the com-
petition with the natural ligand could be to develop a ligand that binds
to an alternative site of the receptor and still be transported. Although
this approach may seem very difﬁcult, proof-of-concept has beenprovided by a transferrin-receptor binding peptide that was then
bound to the surface of a nanoparticle for transport across the blood–
brain barrier [184]. Unfortunately, while the transferrin receptor
(TFRC) and insulin receptor (INSR) are transcytosed across the blood–
brain barrier they are not transcytosed in the intestinal epithelium
[185]. The transferrin receptor is predominantly localized to the
basolateral membrane in enterocytes where it binds transferrin and is
endocytosed [186]. Transferrin is loaded with iron in endosomes and
the transferrin-receptor complex is recycled to the basolateral mem-
brane [186]. Whether an alternative binding site can be used on anoth-
er, more suitable receptor than the transferrin receptor in the
enterocyte remains to be seen. A similar strategy where FCGRT-
binding peptides were fused to therapeutic proteins allowing them to
transcytose across MDCKmonolayers has been explored [108]. Expres-
sion of transcytosed receptors in the intestine is shown in Fig. 8B.
As the number of identiﬁed receptors that are transcytosed in the in-
testinal epithelium is limited, other components of the apical mem-
brane might be utilized for targeted delivery of peptides or
nanoparticles. Glycosphingolipids are constituents of the plasma mem-
brane involved in modulation of intracellular signaling [187,188]. The
ceramide domain of the glycosphingolipid GM1 controls its intracellular
sorting; this is also the case after endocytosis [189,190]. If the ceramide
domain contains a short lipid chain, C12 or below, a fraction of the
glycosphingolipid GM1 is sorted into early and recycling endosomes
after addition to the apical face of the cell [190]. A fraction of the GM-
1 C12-fusion is then transcytosed. If the lipid chain is longer, C18, the
glycosphingolipid is mainly sorted into late endosomes and directed
to the lysosomes [190,191]. Fusing glucagon-like peptide 1 (GLP1) to a
short chain glycosphingolipid GM1 allowed the peptide hormone to
be transcytosed over polarized epithelial MDCK cells and the nasal epi-
thelium in vivo in mice [123].
3.4.4. Nanoparticles and M-cell mediated transcytosis
Recently it was suggested for the ﬁrst time that the body produces
and absorbs endogenous nanoparticles in the small intestine [192,
193]. Phosphate and calcium ions secreted by the intestinal epithelium,
will complex with calcium ions and precipitate as calcium-phosphate
nanoparticles in the gut lumen. It was suggested that these endogenous
nanoparticles trap antigens that are afterwards sampled by M-cells in
Peyer's patches. The nanoparticles are then transcytosed to the antigen
presenting cells located below the patches.
This newly discovered mechanism was proposed as a sampling
mechanism from the intestinal lumen in order to induce immune re-
sponses to luminal antigens when needed and perhaps also tomaintain
food tolerance [93,171]. While the primary role of intestinal lymphoid
tissues such as the Peyer's patches is to mediate immune responses to
antigens and pathogens, these tissues also play a role in the develop-
ment of oral tolerance to food antigens [171].
After transcytosis by the M-cells to the antigen presenting cells, the
endogenous nanoparticles are broken down [192]. While this mecha-
nism can be of interest for peptide delivery to the local immune system
e.g. in oral vaccines, its applicability for systemic delivery remains to be
shown [1,194]. Another question that remains to be answered is the ca-
pacity of the process. When studying peptide absorption across the
human intestinal epithelium, it was found that tissue specimens con-
taining Peyer's patches transported no more than twice the amount of
peptides than did neighboring M-cell free epithelium [195,196]. While
the physiological antigen sampling mechanism might be efﬁcient, the
Peyer's patches constitute a very small fraction of the intestinal surface.
In a young adult, a few hundred patches are found in the ileum; this
number then declines with increasing age [197,198]. Compared to the
surface area covered by enterocytes, the area of the Peyer's patches is
miniscule. The fraction of M-cells compared to other epithelial cells in
the intestine has been estimated to 1 in 10 million cells [199]. The den-
sity of Peyer's patches in the intestine of common laboratory animal
species is several times higher than in man [21]. This difference must
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capacity in man.
M-cell transcytosis has often been seen as a promising route of
nanoparticle delivery, particularly as M-cell transcytosis seems to by-
pass the lysosomes [1,200]. The efﬁciency ofM-cell transcytosis as com-
pared to that of the normal villous epithelium has been compared in a
number of studies. In in vitro experimentswith human intestinal tissues
it was found that the permeability of RGD-peptide decorated nanopar-
ticleswas 5 times higher in tissue specimens containing Peyer's patches
compared to normal villous epithelium [201]. When rat, ovine and bo-
vine villous epithelium and Peyer's patch containing epithelium were
compared, the HRP permeability across the tissue was 5-fold higher
for tissue sections containing patches [202]. Uptake of Salmonella
typhimurium bacteria was 10-fold higher in the Peyer's patches than
in the villous epithelium [202].
In rat intestinal everted sacs, styrene maleic acid nanomicelles
showed identical transport in jejunum and ileum, despite the higher
density of Peyer's patches in the ileum [203]. The nanomicelles were
absorbed to equal extents byM-cells and nearby enterocytes. In another
study, uptake of polyalkylcyanoacrylate nanocapsules in M-cells was
determined to be twice that of uptake in nearby enterocytes [204].
Thus the M-cell capacity for particle uptake seems on par with to ten
times higher than that of the normal villous epithelium. However,
since there is only 1 M-cell in 10 million enterocytes, the total capacity
for nanoparticle uptake in the latter is much higher.
While the extent of Peyer's patch particle uptake seems low, few
studies have been published quantifying the capacity and kinetics of
the process. In one such study a dose of 4 × 108 polystyrene nanopar-
ticles was administered to rabbit intestinal loops with Peyer's
patches [205]. Each loop contained on average 15 Peyer's patches.
After 90 min of exposure nanoparticle uptake into the follicle associ-
ated epithelium of the patch and the underlying subepithelial dome
was quantiﬁed. The most active patch was found to have absorbed
approximately 6000 nanoparticles. If all patches had shown similar
activities 1 in 4500 nanoparticles would have been absorbed, trans-
lating to a very low bioavailability. It was noted in the same study
that rabbit Peyer's patches showed 10-fold higher particle absorp-
tion than mouse patches.
What is the fate of particles after transcytosis across theM-cell? This
was investigated in mice where β-glucan microparticles were taken up
by M-cells and transcytosed into the subepithelial dome of the Peyer's
patch [206]. Here the particles were absorbed by a subset of dendritic
cells. The particles remained in these cells until the end of the experi-
ment, three days later. Polystyrene nanoparticles have also been
found to be associated with dendritic cells up to 14 days after uptake
in a Peyer's patch [207]. This suggests that absorbed particles show lim-
ited transport from the patch into the systemic circulation, but could
possibly be used for pharmacological intervention in dendritic cells.3.5. Subepithelial tissue
The subepithelial tissue resides below the intestinal epithelium, and
can be divided into the lamina propria and mucosa muscularis. In vivo,
this loose and highly vascularized connective tissue is not a rate-
limiting barrier to the passage of small peptides [208,209]. Larger pep-
tides, especially over 30 kDa, are preferentially transported into the
lymphatic system, rather than the blood vessels [209]. In this respect,
intestinal absorption and subcutaneous or intramuscular injections fol-
low the same pattern. The cell density in the subepithelial layer is low,
especially compared to the densely packed epithelial layer (see Figs.
2–8). The extracellular matrix in dense connective tissues such as carti-
lage can be very compact, exhibiting pore sizes as small as 60 nm [210].
However, the pore size of the extracellular matrix in the intestinal
subepithelium is much larger than this and is unlikely to impede nano-
particles to any signiﬁcant extent [211,212].4. Caco-2 cells as an in vitro model system of intestinal absorption
Caco-2 is a human colon cancer cell line that, when cultured on
semi-permeable ﬁlter supports, differentiates into an enterocyte-like
phenotype. Since its introduction, it has become aworkhorse for perme-
ability studies in drug discovery and development as well as in the
ADME (drug absorption, distribution, metabolism and excretion) sci-
ences [213–216]. Well established protocols allow the prediction of
human intestinal fraction absorbed from Caco-2 permeability data as
long as intestinal drug metabolism or active transport is not signiﬁcant
for the investigated drug [217,218]. Caco-2 cells lack expression of the
majority of the drug metabolizing cytochrome P450 enzymes found in
the small intestine, limiting their usefulness for the prediction of oral
bioavailability [14].
We recently quantiﬁed the proteome of ﬁlter-grown Caco-2 cells
[14]. Despite its colonic origin, the Caco-2 cell line shows a proteome ex-
pression proﬁle closer to the jejunal enterocyte. Yet, important differ-
ences exist between the Caco-2 cell line and the intestine. For
instance, a lower expression of brush border peptidases (Section 3.1)
and mucins was observed. Several brush border proteinases and pepti-
dases were below the limit of detection, including dipeptidyl-
peptidases 3 (DPP3), glutamyl aminoopeptidase (ENPEP), membrane
metallo-endopeptidase (MME), and transmembrane protease serine 4
(TMPRSS4) (and others) which are all highly expressed in enterocytes.
Only DPP4 and TMPRSS15 were found at detectable levels in Caco-2
cells (Section 3.2.1). Caco-2metabolism of peptides will therefore likely
be lower compared to that in the human intestine.
Attempts have been made to compensate for the absence of a pro-
tective mucus layer in Caco-2 by co-culture with various mucus
secreting goblet cell clones isolated from the human colorectal adeno-
carcinoma cell line HT-29 [46]. Unfortunately these two cell lines do
notmixwell in culture andHT-29 cells tend to grow as colonies embed-
ded in Caco-2 cells, resulting in a discontinuous mucus layer [219–223].
Co-cultures display lower transepithelial electrical resistance (TEER,
also often given as TER) than pure Caco-2 cultures and also show in-
creased permeability of integrity markers and peptides [222]. The pres-
ence of a mucus layer has been shown to impede nanoparticle
permeability in co-cultures [223]. Considering the discontinuous
mucus layer it is likely that HT-29/Caco-2 co-cultures underestimate
nanoparticle binding to mucus. Monocultures of goblet cell clones
(Table 2) seem, depending on clone to give a better coverage and
have found some application, e.g. in studies of bioadhesive delivery sys-
tems [224,225]. Importantly, the goblet cell clones will not form a
mucus layer that is identical with regard to composition and structure
to those found along the gastrointestinal tract. Therefore, freshly isolat-
ed mucus layers from the region of interest constitute better models
[226]. In addition of having the right composition, freshly isolated
mucus may retain its tertiary structure.
One aspect that has limited the usefulness of Caco-2 cells for studies
of peptide delivery is the comparatively low level of endocytosis and
transcytosis [137,138]. While this may be explained in part by the
physiological barrier function of the intestinal epithelium, the proteome
analysis showed reduced expression of proteins involved in endocyto-
sis, such as caveolins and some syntaxins. Considering the tumor origin
of Caco-2 cells, it is interesting to note that caveolin-1 can act as both a
tumor suppressor and as an oncogene depending on context [227–229].
In the early stage of colorectal cancers, caveolin-1 suppresses tumor
progression, while over-expression of caveolin-1 reduces the
tumourogenicity of more mature colon carcinoma cells, a phenomenon
regulated by promotor methylation density [229]. Our protein expres-
sion analysis is in agreement with other studies showing that caveolins
are down-regulated in differentiated Caco-2 cells [230], but
contradicted by others, where caveolin-1 expression could be detected
by western blotting [136].
Co-culture of Caco-2 cells with Raji B cells (a human hematopoietic
cell line of B lymphocyte origin) induces an M-cell like phenotype in
Table 2
Examples of principally different in vitro model systems of the intestinal barrier.
Caco-2 HT-29 Caco-2 + Raji cells Ussing
Barrier component
Brush border peptidases Reduced expression Reduced expression Reduced expression Normal
Mucus No secreted mucins Secretes MUC2 No secreted mucins Present, but mucin is discharged over time
Glycocalyx Thin Thin Thin Normal
Tight junctions Very tight; low or no
claudin 5 and 8
Tight Tight; Low or no claudin 5 and 8 Normal
Endocytosis Low activity Caveolins
below LOQ
Low activity Increased initial activity;
detectable caveolins
Normal
Subepithelial tissue Absent Absent Absent Partly present; swells with time; lacks circulation,
systemic immune system, and innervation
Technical limitations
Viability Extended Extended Extended Limited to a few hours
Sensitivity to toxic compounds High High High Lower
Availability Good Limited Limited Exclusive
Equipment Standard Standard Standard Specialized
Technical challenge Medium Medium/High High High
LOQ; limit of quantitation.
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type induces transcytotic capacity, the co-cultures have often been used
to study transepithelial transport of antigens, pathogens, peptides, and
nanoparticles. Nanoparticle transport could be increased further if the
particles were decorated with an integrin-binding RGD-peptide [201].
Interestingly, the caveolin expression is increased in the M-cell like
cells [230]. It is not clear towhat extent thismodel represents the follicle
associated epithelium. Since transcytosis in the model can be induced
and stabilized by the addition of pro-inﬂammatory cytokines, it may
also bear characteristics of the acutely inﬂamed intestine [232]. This
is supported by studies in Caco-2 cell monolayers (without Raji B
cells), which after a brief exposure to the enteropathogen Yersinia pseu-
dotuberculosis increased the transport of nanoparticles 30 fold [233].
A triple culture model combining Caco-2, HT-29 and Raji B cells has
been published [223]. As published previously for HT-29/Caco-2 co-
cultures the triple culture model displayed a discontinuous mucus
layer [222]. Polystyrene nanoparticle permeability was not studied in
the triple model but cellular uptake of nanoparticles was determined
to be 50% higher in the triple culturemodel than in pure Caco-2 culture.
However, no statistics were given for this experiment so it is impossible
to judge if this small difference is signiﬁcant.
While Caco-2 cells is the most commonly used cell line for studying
intestinal transport, several other cell lines have been employed in dif-
ferent applications (reviewed in [218]). T84 is a human colonic adeno-
carcinoma with a crypt-like phenotype [234]. The rat 2/4/A1 crypt
cell-like cell line forms a leakier epithelium than the other cell lines de-
scribed and has been used for transport and permeability of small mol-
ecule drugs [235,236]. Dog kidney epithelium derived Madine-Darby
Canine Kidney (MDCK) cells are often used as amodel system for trans-
porter expression and as a model for epithelial transcytosis of macro-
molecules and nanoparticles [106].
4.1. Novel advanced in vitro model systems
In recent years many new cell culture systems have been developed
trying to improve cell phenotypes by mimicking key physiological pa-
rameters such as 3D-geometry, ﬂuid ﬂow and mechanical stimulation
simulating pressure changes caused by the heartbeats.
For example human small intestinal epithelial cell monolayers dif-
ferentiated from adult stem cells have recently been applied to predic-
tion of human oral drug absorption [237]. Interestingly, the epithelial
monolayers showed a more in vivo-like pore size distribution in the
tight junctions than Caco-2 cell monolayers [238]. This implicates that
they might be advantageous to use for permeability studies of low per-
meable compounds such as peptides, provided that they become gener-
ally available.In another culturemodel, different intestinal cell lineswere cultured
at the air-liquid interface in semi-wet cultureswithmechanical stimula-
tion. Both polarization and mucus production were induced in the cell
cultures [239].
Caco-2 cells have also been cultured on micromolded collagen sup-
ports that mimicked villi morphology [240]. This led to increased ex-
pression of the transmembrane mucin MUC17 and the tight junction
protein occludin [240]. MUC17 expression led to an increased protec-
tion against S. typhimurium infection.
The most advanced culture systems developed to date are the
microﬂuidic organs-on-chips [241]. Gut-on-a-chip technology has also
been used with Caco-2 cells [242,243]. The cells are cultured on a semi-
permeable membrane with the apical and basolateral membranes fac-
ing two different ﬂuid-ﬁlled channels simulating intestinal lumen and
blood, respectively. Incorporating pressure pulses to simulate both
heart beat and peristaltic movement leads to dramatic changes in the
Caco-2 cell phenotype. Mucin expression was induced in the cultures
and the Caco-2 cells started to form villous- and crypt-like structures
[242,243]. Further differentiation of the Caco-2 cells into several intesti-
nal cell types, including goblet cells, was observed [242].
In summary, more advanced, specialized cell culture models that
may better mimic the in vivo state than the currently favored models
reviewed here are under development. These novelmodels need conﬁr-
mation and further study but could make signiﬁcant contributions to
the ﬁeld in the future when they are well established. Still, it is difﬁcult
to capture the full complexity of the intestinal epithelium in these
models (Table 2). Could studies of excised human intestinal tissues
mounted in Ussing chambers provide a better model?
5. Ussing chambers
The Ussing chamber (Fig. 9) was devised in 1946 by the Danish
physiologist Hans Henriksen Ussing for the study of water excretion
through toad skin [244,245]. It has since been used for the study of
transport properties, permeability and physiology of diverse epithelial
tissues ranging from the gut to the retina. The Ussing chamber is one
of the most advanced methods for ADME research in vitro and is used
to investigate intestinal integrity and permeability. Very few papers
have been published where Ussing chambers have been used to study
the permeability of nanoparticles (24 in total as of February, 2016)
and only 4 of these studies have used human intestinal tissues [137,
233,246,247]. A handful of studies have used Ussing chambers to
study the permeability of peptides not formulated in nanoparticles,
none of these have been performed using human tissues. Therefore,
some of the examples below have been obtained from Ussing chamber
studies with tissues from experimental animals, usually rodents.
F
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Fig. 9.Ussing chambers A. Schematic drawing of an Ussing chamber. The intestinal tissue sample ismounted in awindowconnecting two buffer-ﬁlled, oxygenated compartments. Peptide
or particle permeation from the donor compartment (here on the left representing the mucosal, apical side) to the receiver compartment (here on the right representing the serosal,
basolateral side) is monitored. The electrophysiological properties transepithelial electrical resistance (TEER), potential difference between the two chambers (resting potential; PD)
and short-circuit current (Isc) of the tissue are used as indicators of tissue integrity and viability and are followed throughout the experiment. B. Photograph of an Ussing chamber
corresponding to the one in A. C. A freshly isolated specimen of human jejunal mucosa before dissection. Note the prominent transversal folds in the presence of the submucosal
muscle layer. D–E. Human jejunal mucosa after dissection which removes the subepithelial muscle layer. D. Mucosal view. Note the absence of transversal folds and the villi along the
edge of the specimen. E. Serosal view. Note the capillary bed. F–G. Electrophysiology readouts during an Ussing experiment. F. Resting potential difference (PD) between the two
chambers. Note the drop in PD, starting around 90 min. F indicates addition of the cAMP-agonist forskolin. The strong electrical response to forskolin indicates good viability of this
tissue specimen. G. Transepithelial electrical resistance (TEER) across the epithelium. Note the drop in TEER during the initial phase of the experiment. This is due to slow warming of
the tissue sample originally mounted at 4 °C and does not indicate a decrease in epithelial integrity.
269P. Lundquist, P. Artursson / Advanced Drug Delivery Reviews 106 (2016) 256–276Ussing chamber studies based on human tissue have traditionally
used colon or ileum resected during cancer surgery. In recent years,
the global obesity epidemic has given access tomore proximal intestinal
segments. This is because different bariatric surgery techniques are now
among themost common procedures in surgery clinics inmany parts of
the world [248]. During Roux-en-Y gastric bypass small jejunum tissue
samples can be donatedwithout risk to the patient. This has led to an in-
crease in the availability of human intestinal tissue for Ussing chamber
experiments. Intestinal tissues from obese patients could possibly
show somewhat higher permeability than intestines in average weight
patients [249,250]. In rodents it is clear that obesity induced by a high
fat diet can lead to a relativelymild inﬂammation in the intestine, some-
times but not always accompanied by a defect in intestinal barrier func-
tion [251]. The severity of the induced inﬂammation seems to be species
and strain dependent [252,253]. The evidence for intestinal inﬂamma-
tion in obese humans is contradictive with several studies giving con-
ﬂicting results with no clear indication of barrier defects [250]. Obesepatients with non-alcoholic steatosis have shown evidence of a mild
barrier defect that was not observed in obese or lean patients. [254]
While induced obesity in rodents is an acute phenomenon following
an extreme diet, most obese humans have been overweight for many
years prior to bariatric surgery. It is therefore likely that the intestinal in-
ﬂammation in human obese patients is milder with smaller effects on
tissue integrity.
It is of great importance that the laboratory performing the Ussing
chamber experiments is situated in close proximity to the surgery or
clinic as the tissues rapidly deteriorate after surgical resection. Trans-
portation should occur under well-deﬁned conditions and should take
no longer than 30–60 min in order to avoid decreased tissue viability
and integrity [255,256].
The Ussing chamber technique is not only logistically, but also tech-
nically challenging [255–257]. The intestinal epithelium from freshly
excised tissue has to be dissected from the underlying tissues along
the submucosa and mounted so that it covers a window between two
270 P. Lundquist, P. Artursson / Advanced Drug Delivery Reviews 106 (2016) 256–276adjacent chambers (Fig. 9). The chambers are ﬁlled with a buffer con-
taining nutrients needed by the tissue; this is commonly Krebs-Ringer,
supplemented with amino acids, warmed to 37 °C, and bubbled with
oxygen or carbogen. Ussing chambers are available both in vertical
(Fig. 9) and horizontal (not shown) formats [202,257]. Horizontal
Ussing chambers are essentially identical to Franz diffusion cells with
the addition of electrophysiological monitoring. Franz diffusion cells
are mainly used for skin permeability studies but have been used with
intestinal tissues as well [202,258]. Peptides, nanoparticles or other
materials of interest are added to the chamber on the apical (mucosal)
side of the tissue and their passage over the epithelium and appearance
in the basolateral (serosal) chamber is monitored. From these
concentration-time data, the apparent permeability rate constant
(Papp) can be calculated [217,255].
Care must be taken to ensure the continued viability and integrity of
the tissue. As in cell monolayers, this is usually achieved by monitoring
the permeability of hydrophilicmarkers (a low permeability is associat-
ed with intact tissue) and measuring the electrophysiological parame-
ters of the tissue (Fig. 9). The commonly used electrophysiological
read out trans-epithelial electrical resistance (TEER) is a comparatively
blunt tool with which to monitor epithelial integrity, so the use of hy-
drophilic permeability markers is highly recommended [257]. A com-
mon technique to monitor tissue viability at the end of an experiment
is to add the cAMP-agonist forskolin. If the tissue is still viable, the in-
duced increase in cAMP will stimulate the current passing over the ep-
ithelium, mainly by activation of CFTR (Cystic ﬁbrosis transmembrane
conductance regulator, ABCC7) Cl− channels (Fig. 9) [259].
Cytotoxicity readouts such as ATP levels, lactate dehydrogenase
(LDH) release and apoptosis detection can be used in Ussing chambers.
Such assays are thought to give more physiologically relevant data on
acute toxic effects than can be achieved in cell culture since the latter
are often more sensitive to xenobiotics, pharmaceutical excipients and
nanoparticle formulations [260,261,262]. The use of human tissue also
presents other advantages, as many of the intestinal tissue functions
are preserved (see Table 2). These responses are often species speciﬁc,
especially in the case of peptide metabolism, inﬂammatory response
and cytokine release after exposure to e.g. toxic nanoparticles. After a
permeability measurement in an Ussing chamber, the tissue can be
processed for microscopy and absorbed peptides or nanoparticles can
be visualized by light, ﬂuorescence, or electron microscopy.
It is important to note that, in several cases, ex vivo experiments
with Ussing chambers are unable to recapture the in vivo situation.
The viability of tissue in the chamber, even under conditions carefully
mimicking physiological conditions, is typically limited to up to 3 h
[255–257]. If maintained for longer times, gradual shedding of the
loosely attached mucosa and emptying of goblet cells will increase.
Excised intestinal tissues are devoid of functional circulation and
lymphatic drainage. This leads to water accumulation and concomitant
tissue swelling in theUssing chamber [257].Water accumulation can be
reduced by substituting glucosewithmannitol in the buffer bathing the
mucosal, apical, surface of the tissue. The absence of glucose shuts down
sodium-dependent glucose transport into the epitheliumand thus sodi-
um and glucose accumulation in the serosal chamber; this reduces the
buildup of an osmotic gradient and reduces swelling of the tissue
[257]. It is likely that the lack of circulation can impede passage of espe-
cially largermolecules through the subepithelial layer and it is thus pos-
sible that the subepithelium presents more of a barrier in ex vivo
experiments than it does in vivo. In addition, the tissue specimens lack
innervation and the subepithelialmuscle layer. Therefore, responses de-
pendent on nerve signaling and peristaltic movements, respectively,
will not be captured ex vivo. Further, as the tissue lacks circulation, tox-
icologic responses dependent on the systemic immune system cannot
be studied.
In summary, correctly handled, freshly isolated human tissues
mounted in Ussing chambers provide a sensitive system that provides
more of the complexity of the human intestinal barrier in vivo thancell culturemodels. A downside of this complexity is the technical chal-
lenge of the system, which limits its capacity. The Ussing chamber re-
mains a low throughput tool and therefore, as much information as
possible should be extracted from each experiment.
5.1. Translation from Ussing chamber experiments to in vivo intestinal
absorption
An advantage of using human intestinal tissues in Ussing chambers
is that it enables prediction of intestinal absorption inman formolecules
with signiﬁcant intestinal metabolism, such as peptides [255,263]. The
translation of permeability experiments in Ussing chambers to in vivo
intestinal absorption has therefore been established for small drugmol-
ecules in both rat and human [255,264]. When comparing the perme-
ability of small tripeptides (Ile-Pro-Pro and Val-Pro-Pro) in Caco-2
monolayers, rat intestinal tissue ex vivo and perfused jejunal loops, it
was found that Ussing chamber permeabilities were 5–10 fold higher
than the corresponding values derived from Caco-2 measurements
[196]. The permeabilities in the jejunal loops were not signiﬁcantly dif-
ferent frommeasurements from the Ussing chambers. Further, the per-
meabilities in the jejunal loops were comparable to those observed in
in vivo experiments. Interestingly, the more controlled conditions in
the Ussing chamber experiments resulted in lower variability in perme-
ability values than the in vivo experiments. The good in vitro–in vivo
correlation suggested that the subepithelial tissue barrier in the Ussing
chambers did not inﬂuence the permeability measurements of these
small peptides to a signiﬁcant extent under the applied conditions.
The number of studies performed with human tissues in Ussing
chambers is too small to draw deﬁnitive conclusions about their appli-
cability in studies of larger peptide drugs and nanoparticles. Some
promising results have, however, been obtained. Ussing chambers
have been used for prediction of peptide absorption for e.g. IgG mono-
clonal antibodies [265]. Hornby and coworkers investigated the expres-
sion of FcRn in different segments of the intestine from the duodenum
to the distal colon in rat, cymologous monkeys and man. Segmental ex-
pression levels of FcRnwere predictive of Ussing chamber IgGmonoclo-
nal antibody (mAb) permeability over tissues derived from different
parts of the small intestine for human, rat and cymologous monkeys.
Additionally, regional absorption of antibodies showed the same rank
order after instillation in different intestinal segments of cymologous
monkeys. In human tissue experiments, both FcRn expression and
transepithelial transport of IgG mAb in Ussing chambers increased
from the duodenum and distally towards the colon. Thus, in this case,
the regional IgG mAb absorption could be predicted from Ussing cham-
ber experiments and FcRn expression data. If the large size of mAbs is
considered, it seems likely that Ussing chambers can be used to study
the permeability of other large, soluble, peptides too.
A few studies of nanoparticle-mediated intestinal absorption have
been performed in Ussing chambers, mainly using rodent tissue. Studies
of paclitaxel loaded PEG-ylated cyclodextrin poly(anhydride) nanopar-
ticles (where cyclodextrin-paclitaxel complexes were used to increase
drug loading and the PEG-ylated surface aimed at mucodiffusivity)
established a rank order correlation between permeabilities of different
nanoparticle constructs and rat plasma AUC of paclitaxel after in vivo
administration [266]. In another study, nanoparticles were derived
from trimethyl chitosan (for permeation enhancement) and stabilized
with poly γ-glutamic acid [267]. This backbone was conjugated to
FOY-251, an active derivative of camostat mesylate, for peptidase inhi-
bition purposes. The nanoparticles were decorated with a goblet cell
targeting peptide, and loaded with insulin (mean ﬁnal diameter of
250–300 nm). In this case, studies in Ussing chamber mounted rat jeju-
nal tissues were used to predict the nanoparticle construct that would
give the most efﬁcient insulin-delivery in in vivo rat studies.
In a third study, calcitonin-loaded solid lipid nanoparticles with
densely PEG-ylated surfaces were decorated with a goblet cell targeting
peptide or a CPP (mean diameters of 240–400 nm) [268]. Ussing
271P. Lundquist, P. Artursson / Advanced Drug Delivery Reviews 106 (2016) 256–276chamber experiments with rat duodenum could here predict the rank
order and fold increase in in vivo rat bioavailability when comparing
free calcitonin, solid lipid nanoparticles, goblet cell targeting peptide
decorated solid lipid nanoparticles, and CPP-decorated solid lipid
nanoparticles.
In a fourth study, Ussing chamber experiments were performed
usinghuman colonic tissues from inﬂammatory bowel disease (IBD)pa-
tients. PLGA nanoparticles (250 nm) andmicroparticles (3 μm) showed
very limited permeability (measured in the receiving chamber of the
Ussing chamber) in normal epithelium, while they showed increased
permeability in the corresponding inﬂamed epithelium [246]. Penetra-
tion was measured as the number of particles found in microscopy
sections of tissue specimens after exposure in Ussing chambers.
Penetration, like permeability, increased signiﬁcantly in the inﬂamed
epithelium. Similarly, after in vivo administration of nano- and micro-
particles to the colon of IBD patients, only a few nanoparticles could
be seen in the mucosa of patients with ulcerative colitis in remission.
A larger accumulation of nanoparticles could be seen at active inﬂamed
sites. Very few microparticles could be detected in the mucosa of
Crohn's disease (CD) patients with mild inﬂammation. In rectal lesions
in CD patients with severe inﬂammation a pronounced accumulation
of microparticles could be seen, correlating well with the results from
the Ussing chambers.
Tissue penetration and permeability also increased in the normal
human ileum after a brief exposure to the enteropathogenic bacterium
Y. pseudotuberculosis, presumably as a result of an acute inﬂammatory
response [233]. The enhanced transepithelial transport was inhibited
by the commonly used but unselective endocytosis inhibitor 5-(N-
ethyl-N-isopropyl) amiloride (EIPA), indicating the involvement of an
endocytotic mechanism, possibly macropinocytosis [141,233].
PEG-functionalized, chitosan-functionalized, and non-functionalized
PLGA nano- andmicroparticles were also used in Ussing chamber exper-
imentswith colon tissue biopsies derived frompatientswith IBD. It could
be shown that PEG-ylation increased tissue permeation and penetration
in Ussing chamber experiments [247]. In this study, neither nano- nor
micro-PLGA particles (250 nm and 3 μm, respectively) showed any per-
meability over colonic epithelium. Healthy and inﬂamed colons were
both impermeable to the PLGA nanoparticles. Both PEG-ylated nano-
and microparticles showed permeability over the inﬂamed mucosa
and, to a small extent over the healthy epithelium. Nanoparticles were
more permeable than the microparticles in both tissue types. The same
pattern was found in microscopy analysis of tissue samples from the
Ussing chambers. Inﬂamed mucosa contained many more particles
(both micro and nano) than healthy tissue. In all cases, nanoparticles
were detected in higher numbers in the tissue than microparticles. The
data suggests that the PEG-ylated particles hadmucus penetrating prop-
erties because of their short, 5 kDa PEG-chains, as discussed in
Section 3.2.2 and therefore they could penetrate the mucus layer to in-
teract with the epithelium. Chitosan-functionalized positively chargedintestinal lumen
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Fig. 10. Prediction of intestinal regional fraction absorbed from Papp values derived fromUssing
[14]. A. shows a schematic drawing of the model. B. Predicted fraction absorbed as a function of
typical of nanoparticles is shown.nano- and microparticles showed a pronounced binding to mucus and
cell surfaces preventing the permeability and uptake of these particles.
In summary, these results show a good in vitro–in vivo agreement
between nanoparticle uptake in normal as well as inﬂamed human in-
testinal tissue. They also show that the uptake of non-targeted nanopar-
ticles increases, but remains low, in IBD.6. Modeling of jejunal peptide or nanoparticle absorption
In a recent study, we introduced a simplemechanisticmodel for pre-
diction of the intestinal regional fraction absorbed from permeability
(Papp) values derived from Caco-2 or Ussing chamber experiments
[14]. The model was set up to mimic a typical human intestinal perfu-
sion experiment in a 10-cm intestinal segment (loc-i-gut) [96,
269].The model assumes a transit time of 270 min, that the permeant
is in solution and stable, evenly distributed in the lumen during the
study, and that the transport rates are in the linear range. Based on
these assumptions the fraction absorbed from the perfusate can be pre-
dicted. Comparing themodel to previously published Ussing permeabil-
ity studies revealed a good correspondence to human in vivo fraction
absorbed values [255].
The geometry of the intestinal segment modeled is illustrated in
Fig. 10A. Fig. 10B shows the predicted fraction absorbed as a function
of intestinal permeability. The intestinal fraction absorbed increases
from 1% to 99.5% when the permeability coefﬁcient (Papp) increases
from 0.5 to 100 × 10−6 cm/s. Most peptides and nanoparticles show
low Papp values that are predicted to correspond to low (far below
1%) absorbed fractions in vivo. Exceptions to this general statement
exist, notably, the insulin permeation studies conducted after MLCP in-
hibition by Taverner and coworkers [66] as well as the utilization of
targeted nanoparticles such as the IgG Fc-decorated nanoparticles
used to achieve FcRn mediated nanoparticle transcytosis performed by
Pridgen et al., [109].
In the study of Taverner et al., an insulin bioavailability of 3–4% after
tight junction modulation was calculated, corresponding to a Papp
value of 0.8–0.9 × 10−6 cm/s [66]. In the study of Pridgen et al., the bio-
availability was not calculated for the Fc-decorated nanoparticles [109].
However, considering that the dose of 1.1 IU/kg insulin corresponds to
a typical daily subcutaneous dose in man, and the resulting decrease in
blood glucose was 45%, it is likely that the bioavailability N25%, corre-
sponding to a Papp value N5 × 10−6 cm/s. Targeting of peptide or
nanoparticles to the vitamin B12 absorption pathway resulted in bio-
availabilities estimated to be in the range of 5–25% [113,115,116,180].
This corresponds to Papp values in the range of 1–5 × 10−6 cm/s. A
bias inherent in our simple predictions is that the model assumes expo-
sure to a constant concentration of the respective delivery system. In
vivo, an added complexity is that the concentration will vary over time.
Finally, it is note-worthy that these studies were performed in small10 10
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chamber experiments. Predictionsweremade using themodel described in Ölander et al.
permeability coefﬁcient (Papp) C. An enlargement of the graph for the lower Papp values
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ing man.
7. Summary and conclusions
There are signiﬁcant physiological and biochemical barriers to pep-
tide absorption in the gastrointestinal tract. Nanoparticles have often
been seen as a tool to overcome these barriers. Our review shows that
to be effective, such nanoparticles must possess certain characteristics.
First they must be able to protect their cargo against enzymatic break-
down in the gut lumen and by intestinal cells. Second, they should pos-
sess characteristics that allow them to pass or deliver the peptide across
the mucus barrier. Finally, they should pass the intestinal epithelium
lining the intestinal lumen. To circumvent this problem, many oral pep-
tide delivery systems in current clinical trials have incorporated absorp-
tion enhancers with more or less non-speciﬁc mechanisms of action in
their formulations. Here, we have reviewed alternative approaches
and identiﬁed complex but more speciﬁc principles for oral peptide de-
livery, in particular in nanoparticles.
To pass the epithelial layer two strategies have been usedwith some
success: the paracellular route via the tight junctions and the transcellu-
lar transcytosis route. Tight junctions can be modulated by MLC phos-
phorylation via MLCP inhibition, resulting in signiﬁcant absorption of
peptides. The transcellular pathways via comparably well investigated
transcytotic pathways such as those for vitamin B12 and IgGwere iden-
tiﬁed as themost promising options for the oral delivery of peptides en-
capsulated in nanoparticles. Importantly, to become a viable alternative
for oral peptide delivery to humans, the promising results observed
with tight junction regulation and transcytosis in small animals must
be translatable to man.
Acknowledgment
This work was supported by The European Union Seventh Frame-
work Programme Trans-Int (grant agreement number NMP4-LA-
2012-281035) and the Swedish Research Council (no. 2822).
We thank our clinical collaborators, Professor Magnus Sundbom
(Department of Surgical Sciences, Upper Abdominal Surgery, Uppsala
University) and coworkers, and Professor Mikael Wirén (Vrinnevi
Hospital, Norrköping and Department of Clinical and Experimental
Medicine, Oncology, Linköping University) and coworkers for their ex-
cellent helpwith tissue collection. The helpwith Ussing chamber exper-
iments by the group of Professor Johan D Söderholm and Åsa Keita
(Department of Clinical and Experimental Medicine, Division of
Surgery, Linköping University) is gratefully acknowledged. The authors
are indebted to Ivailo Simoff, Georgiy Khodus and Magnus Ölander,
Department of Pharmacy, Uppsala University for their help in many as-
pects of this work.
References
[1] A.A. Date, J. Hanes, L.M. Ensign, Nanoparticles for oral delivery: design, evaluation
and state-of-the-art, J. Control. Release (2016).
[2] H. Sinnecker, T. Krause, S. Koelling, I. Lautenschläger, A. Frey, The gut wall provides
an effective barrier against nanoparticle uptake, Beilstein J. Nanotechnol. 5 (2014)
2092–2101.
[3] X. Hu, W. Fan, Z. Yu, Y. Lu, J. Qi, J. Zhang, X. Dong, W. Zhao, W. Wu, Evidence does
not support absorption of intact solid lipid nanoparticles via oral delivery,
Nanoscale 8 (2016) 7024–7035.
[4] N. Tsomaia, Peptide therapeutics: targeting the undruggable space, Eur. J. Med.
Chem. 94 (2015) 459–470.
[5] B.C. Doak, B. Over, F. Giordanetto, J. Kihlberg, Oral druggable space beyond the rule
of 5: insights from drugs and clinical candidates, Chem. Biol. 21 (2014) 1115–1142.
[6] K. Palm, P. Stenberg, K. Luthman, P. Artursson, Polar molecular surface properties
predict the intestinal absorption of drugs in humans, Pharm. Res. 14 (1997)
568–571.
[7] Physiology of the Gastrointestinal Tract, Raven Press, 2006.
[8] P.R. Kiela, F.K. Ghishan, Physiology of intestinal absorption and secretion, Best
Pract. Res. Clin. Gastroenterol. 30 (2016) 145–159.[9] B.E. Goodman, Insights into digestion and absorption of major nutrients in
humans, Adv. Physiol. Educ. 34 (2010) 44–53.
[10] H.J. Binder, A. Reuben, Nutrient digestion and absorption, in: W.F. Boron, E.L.
Boulpaep (Eds.), Medical Physiology, Elsevier, Philadelphi, PA, USA 2012,
pp. 949–979.
[11] D.C. Whitcomb, M.E. Lowe, Human pancreatic digestive enzymes, Dig. Dis. Sci. 52
(2007) 1–17.
[12] M. Uhlén, L. Fagerberg, B.M. Hallström, C. Lindskog, P. Oksvold, A. Mardinoglu, Å.
Sivertsson, C. Kampf, E. Sjöstedt, A. Asplund, Tissue-based map of the human pro-
teome, Science 347 (2015) 1260419.
[13] M. Uhlen, P. Oksvold, L. Fagerberg, E. Lundberg, K. Jonasson, M. Forsberg, M.
Zwahlen, C. Kampf, K. Wester, S. Hober, Towards a knowledge-based human pro-
tein atlas, Nat. Biotechnol. 28 (2010) 1248–1250.
[14] M. Ölander, J.R. Wiśniewski, P. Matsson, P. Lundquist, P. Artursson, The proteome
of ﬁlter-grown Caco-2 cells with a focus on proteins involved in drug disposition,
J. Pharm. Sci. (2016).
[15] I. Hubatsch, L. Lazorova, A. Vahlne, P. Artursson, Orally active antiviral tripeptide
glycyl-prolyl-glycinamide is activated by CD26 (dipeptidyl peptidase IV) before
transport across the intestinal epithelium, Antimicrob. Agents Chemother. 49
(2005) 1087–1092.
[16] A. Bak, O.S. Gudmundsson, G.J. Friis, T.J. Siahaan, R.T. Borchardt, Acyloxyalkoxy-
based cyclic prodrugs of opioid peptides: evaluation of the chemical and enzymatic
stability as well as their transport properties across Caco-2 cell monolayers, Pharm.
Res. 16 (1999) 24–29.
[17] A.L. Ungell, A. Andreasson, K. Lundin, L. Utter, Effects of enzymatic inhibition and
increased paracellular shunting on transport of vasopressin analogues in the rat,
J. Pharm. Sci. 81 (1992) 640–645.
[18] M. Koziolek, M. Grimm, F. Schneider, P. Jedamzik, M. Sager, J.-P. Kühn, W.
Siegmund, W. Weitschies, Navigating the human gastrointestinal tract for oral
drug delivery: uncharted waters and new frontiers, Adv. Drug Deliv. Rev. 101
(2016) 75–88.
[19] S. Davis, J. Hardy, J. Fara, Transit of pharmaceutical dosage forms through the small
intestine, Gut 27 (1986) 886–892.
[20] H.C. Lin, C. Prather, R.S. Fisher, J.H. Meyer, R.W. Summers, M. Pimentel, R.W.
Mccallum, L.M. Akkermans, V. Loening-Baucke, A.T.F.C.o.G. Transit, Measurement
of gastrointestinal transit, Dig. Dis. Sci. 50 (2005) 989–1004.
[21] T.T. Kararli, Comparison of the gastrointestinal anatomy, physiology, and biochem-
istry of humans and commonly used laboratory animals, Biopharm. Drug Dispos.
16 (1995) 351–380.
[22] T. Takashima, T. Shingaki, Y. Katayama, E. Hayashinaka, Y. Wada, M. Kataoka, D.
Ozaki, H. Doi, M. Suzuki, S. Ishida, Dynamic analysis of ﬂuid distribution in the gas-
trointestinal tract in rats: positron emission tomography imaging after oral admin-
istration of nonabsorbable marker, [18F] deoxyﬂuoropoly (ethylene glycol), Mol.
Pharm. 10 (2013) 2261–2269.
[23] H. Lennernäs, C.-G. Regårdh, Regional gastrointestinal absorption of the beta-
blocker pafenolol in the rat and intestinal transit rate determined by movement
of 14C-polyethylene glycol (PEG) 4000, Pharm. Res. 10 (1993) 130–135.
[24] C. Picard, J. Wysocki, J. Fioramonti, N. Grifﬁths, Intestinal and colonic motor alter-
ations associated with irradiation-induced diarrhoea in rats, Neurogastroenterol.
Motil. 13 (2001) 19–26.
[25] T. Aguirre, D. Teijeiro-Osorio, M. Rosa, I. Coulter, M. Alonso, D. Brayden, Current sta-
tus of selected oral peptide technologies in advanced preclinical development and
in clinical trials, Adv. Drug Deliv. Rev. 106 (2016) 223–241.
[26] T.A. Aguirre, M. Rosa, I.S. Coulter, D.J. Brayden, In vitro and in vivo preclinical eval-
uation of a minisphere emulsion-based formulation (SmPill®) of salmon calcito-
nin, Eur. J. Pharm. Sci. 79 (2015) 102–111.
[27] I. Toth, J.P. Malkinson, N.S. Flinn, B. Drouillat, A. Horvath, J. Erchegyi, M. Idei, A.
Venetianer, P. Artursson, L. Lazorova, B. Szende, G. Keri, Novel lipoamino acid- and
liposaccharide-based system for peptide delivery: application for oral administration
of tumor-selective somatostatin analogues, J. Med. Chem. 42 (1999) 4010–4013.
[28] T. Pelaseyed, J.H. Bergström, J.K. Gustafsson, A. Ermund, G.M. Birchenough, A.
Schütte, S. Post, F. Svensson, A.M. Rodríguez-Piñeiro, E.E. Nyström, The mucus
and mucins of the goblet cells and enterocytes provide the ﬁrst defense line of
the gastrointestinal tract and interact with the immune system, Immunol. Rev.
260 (2014) 8–20.
[29] M.E. Johansson, D. Ambort, T. Pelaseyed, A. Schütte, J.K. Gustafsson, A. Ermund, D.B.
Subramani, J.M. Holmén-Larsson, K.A. Thomsson, J.H. Bergström, Composition and
functional role of the mucus layers in the intestine, Cell. Mol. Life Sci. 68 (2011)
3635–3641.
[30] A.P. Corﬁeld, Mucins: a biologically relevant glycan barrier in mucosal protection,
Biochim. Biophys. Acta Gen. Subj. 1850 (2015) 236–252.
[31] N. Jonckheere, N. Skrypek, F. Frénois, I. Van Seuningen, Membrane-bound mucin
modular domains: from structure to function, Biochimie 95 (2013) 1077–1086.
[32] J.R. Wiśniewski, P. Ostasiewicz, K. Duś, D.F. Zielińska, F. Gnad, M. Mann, Extensive
quantitative remodeling of the proteome between normal colon tissue and adeno-
carcinoma, Mol. Syst. Biol. 8 (2012).
[33] M.E. Johansson, G.C. Hansson, Mucus and the goblet cell, Dig. Dis. 31 (2013)
305–309.
[34] D. Ambort, M.E. Johansson, J.K. Gustafsson, H.E. Nilsson, A. Ermund, B.R. Johansson,
P.J. Koeck, H. Hebert, G.C. Hansson, Calcium and pH-dependent packing and release
of the gel-forming MUC2 mucin, Proc. Natl. Acad. Sci. 109 (2012) 5645–5650.
[35] L.A. van der Waaij, H.J. Harmsen, M. Madjipour, F.G. Kroese, M. Zwiers, H. Van
Dullemen, N. De Boer, G. Welling, P.L. Jansen, Bacterial population analysis of
human colon and terminal ileum biopsies with 16S rRNA-based ﬂuorescent
probes: commensal bacteria live in suspension and have no direct contact with ep-
ithelial cells, Inﬂamm. Bowel Dis. 11 (2005) 865–871.
273P. Lundquist, P. Artursson / Advanced Drug Delivery Reviews 106 (2016) 256–276[36] S.K. Lai, Y.-Y. Wang, J. Hanes, Mucus-penetrating nanoparticles for drug and gene
delivery to mucosal tissues, Adv. Drug Deliv. Rev. 61 (2009) 158–171.
[37] C. Atuma, V. Strugala, A. Allen, L. Holm, The adherent gastrointestinal mucus gel
layer: thickness and physical state in vivo, Am. J. Physiol. Gastrointest. Liver Phys-
iol. 280 (2001) G922–G929.
[38] G.C. Hansson, M.E. Johansson, The inner of the twoMuc2mucin-dependent mucus
layers in colon is devoid of bacteria, Gut Microbes 1 (2010) 51–54.
[39] B.H. Bajka, N.M. Rigby, K.L. Cross, A. Macierzanka, A.R. Mackie, The inﬂuence of
small intestinal mucus structure on particle transport ex vivo, Colloids Surf. B:
Biointerfaces 135 (2015) 73–80.
[40] Z. Hong, B. Chasan, R. Bansil, B.S. Turner, K.R. Bhaskar, N.H. Afdhal, Atomic forcemi-
croscopy reveals aggregation of gastric mucin at low pH, Biomacromolecules 6
(2005) 3458–3466.
[41] J.R. Gum, J. Byrd, J.W. Hicks, N. Toribara, D. Lamport, Y. Kim, Molecular cloning of
human intestinal mucin cDNAs. Sequence analysis and evidence for genetic poly-
morphism, J. Biol. Chem. 264 (1989) 6480–6487.
[42] M. Rong, E.A. Rossi, J. Zhang, R.R. McNeer, J.M. van den Brande, M. Yasin, D.T.Weed,
C.A. Carothers Carraway, J.F. Thompson, K.L. Carraway, Expression and localization
of Muc4/sialomucin complex (SMC) in the adult and developing rat intestine: im-
plications for Muc4/SMC function, J. Cell. Physiol. 202 (2005) 275–284.
[43] M.R. Neutra, N.J. Mantis, A. Frey, P.J. Giannasca, The composition and function of M
cell apical membranes: implications for microbial pathogenesis, Semin. Immunol.
11 (1999) 171–181.
[44] A. Frey, K.T. Giannasca, R. Weltzin, P.J. Giannasca, H. Reggio, W.I. Lencer, M.R.
Neutra, Role of the glycocalyx in regulating access of microparticles to apical plas-
ma membranes of intestinal epithelial cells: implications for microbial attachment
and oral vaccine targeting, J. Exp. Med. 184 (1996) 1045–1059.
[45] I. Chantret, A. Barbat, E. Dussaulx, M.G. Brattain, A. Zweibaum, Epithelial polarity,
villin expression, and enterocytic differentiation of cultured human colon carcino-
ma cells: a survey of twenty cell lines, Cancer Res. 48 (1988) 1936–1942.
[46] T.E. Phillips, C. Huet, P.R. Bilbo, D.K. Podolsky, D. Louvard, M.R. Neutra, Human in-
testinal goblet cells in monolayer culture: characterization of a mucus-secreting
subclone derived from the HT29 colon adenocarcinoma cell line, Gastroenterology
94 (1988) 1390–1403.
[47] G. Birchenough,M.E. Johansson, J. Gustafsson, J. Bergström, G. Hansson, Newdevel-
opments in goblet cell mucus secretion and function, Mucosal Immunol. 8 (2015)
712–719.
[48] M.A. Vieira, T.A. Gomes, A.J. Ferreira, T. Knöbl, A.L. Servin, V. Liévin-Le Moal, Two
atypical enteropathogenic Escherichia coli strains induce the production of secreted
and membrane-bound mucins to beneﬁt their own growth at the apical surface of
human mucin-secreting intestinal HT29-MTX cells, Infect. Immun. 78 (2010)
927–938.
[49] P.C. Grifﬁths, B. Cattoz, M.S. Ibrahim, J.C. Anuonye, Probing the interaction of nano-
particles with mucin for drug delivery applications using dynamic light scattering,
Eur. J. Pharm. Biopharm. 97 (2015) 218–222.
[50] O. Lieleg, I. Vladescu, K. Ribbeck, Characterization of particle translocation through
mucin hydrogels, Biophys. J. 98 (2010) 1782–1789.
[51] J.S. Fordtran, T.W. Locklear, Ionic constituents and osmolality of gastric and small-
intestinal ﬂuids after eating, Am. J. Dig. Dis. 11 (1966) 503–521.
[52] H.M. Yildiz, L. Speciner, C. Ozdemir, D.E. Cohen, R.L. Carrier, Food-associated stimuli
enhance barrier properties of gastrointestinal mucus, Biomaterials 54 (2015) 1–8.
[53] S.S. Datta, A.P. Steinberg, R.F. Ismagilov, Polymers in the gut compress the colonic
mucus hydrogel, Proc. Natl. Acad. Sci. (2016) 201602789.
[54] S.S. Olmsted, J.L. Padgett, A.I. Yudin, K.J. Whaley, T.R. Moench, R.A. Cone, Diffusion
of macromolecules and virus-like particles in human cervical mucus, Biophys. J.
81 (2001) 1930–1937.
[55] S.K. Lai, Y.-Y. Wang, K. Hida, R. Cone, J. Hanes, Nanoparticles reveal that human
cervicovaginal mucus is riddled with pores larger than viruses, Proc. Natl. Acad.
Sci. 107 (2010) 598–603.
[56] Q. Xu, L.M. Ensign, N.J. Boylan, A. Schön, X. Gong, J.-C. Yang, N.W. Lamb, S. Cai, T. Yu,
E. Freire, Impact of surface polyethylene glycol (PEG) density on biodegradable
nanoparticle transport in mucus ex vivo and distribution in vivo, ACS Nano 9
(2015) 9217–9227.
[57] L.M. Ensign, B.C. Tang, Y.-Y. Wang, A.T. Terence, T. Hoen, R. Cone, J. Hanes, Mucus-
penetrating nanoparticles for vaginal drug delivery protect against herpes simplex
virus, Sci. Transl. Med. 4 (2012) 138ra179.
[58] J.C. Swavola, T.D. Edwards, M.A. Bevan, Direct measurement of macromolecule-
coated colloid–mucus interactions, Langmuir 31 (2015) 9076–9085.
[59] W. Shan, X. Zhu, M. Liu, L. Li, J. Zhong, W. Sun, Z. Zhang, Y. Huang, Overcoming the
diffusion barrier of mucus and absorption barrier of epithelium by self-assembled
nanoparticles for oral delivery of insulin, ACS Nano 9 (2015) 2345–2356.
[60] P. Artursson, S.D. Knight, Breaking the intestinal barrier to deliver drugs, Science
347 (2015) 716–717.
[61] J.R. Turner, M.M. Buschmann, I. Romero-Calvo, A. Sailer, L. Shen, The role of molec-
ular remodeling in differential regulation of tight junction permeability, Semin.
Cell Dev. Biol. 36 (2014) 204–212.
[62] C. Barmeyer, J.D. Schulzke, M. Fromm, Claudin-related intestinal diseases, Semin.
Cell Dev. Biol. 42 (2015) 30–38.
[63] D. Günzel, S. Alan, Claudins and the modulation of tight junction permeability,
Physiol. Rev. 93 (2013) 525–569.
[64] R.J. Mrsny, G.T. Brown, K. Gerner-Smidt, A.G. Buret, J.B. Meddings, C. Quan, M.
Koval, A. Nusrat, A key claudin extracellular loop domain is critical for epithelial
barrier integrity, Am. J. Pathol. 172 (2008) 905–915.
[65] H. Suzuki, T. Nishizawa, K. Tani, Y. Yamazaki, A. Tamura, R. Ishitani, N. Dohmae, S.
Tsukita, O. Nureki, Y. Fujiyoshi, Crystal structure of a claudin provides insight into
the architecture of tight junctions, Science 344 (2014) 304–307.[66] A. Taverner, R. Dondi, K. Almansour, F. Laurent, S.-E. Owens, I.M. Eggleston, N.
Fotaki, R.J. Mrsny, Enhanced paracellular transport of insulin can be achieved via
transient induction of myosin light chain phosphorylation, J. Control. Release 210
(2015) 189–197.
[67] M. Eto, Regulation of cellular protein phosphatase-1 (PP1) by phosphorylation of
the CPI-17 family, C-kinase-activated PP1 inhibitors, J. Biol. Chem. 284 (2009)
35273–35277.
[68] A.L. Lameris, S. Huybers, K. Kaukinen, T.H. Mäkelä, R.J. Bindels, J.G. Hoenderop, P.I.
Nevalainen, Expressionproﬁlingof claudins in thehumangastrointestinal tract inhealth
and during inﬂammatory bowel disease, Scand. J. Gastroenterol. 48 (2013) 58–69.
[69] A. Tamura, H. Hayashi, M. Imasato, Y. Yamazaki, A. Hagiwara, M.Wada, T. Noda, M.
Watanabe, Y. Suzuki, S. Tsukita, Loss of claudin-15, but not claudin-2, causes Na+
deﬁciency and glucose malabsorption in mouse small intestine, Gastroenterology
140 (2011) 913–923.
[70] S. Noda, S. Tanabe, T. Suzuki, Naringenin enhances intestinal barrier function
through the expression and cytoskeletal association of tight junction proteins in
Caco-2 cells, Mol. Nutr. Food Res. 57 (2013) 2019–2028.
[71] C.R. Weber, D.R. Raleigh, L. Su, L. Shen, E.A. Sullivan, Y. Wang, J.R. Turner, Epithelial
myosin light chain kinase activation induces mucosal interleukin-13 expression to
alter tight junction ion selectivity, J. Biol. Chem. 285 (2010) 12037–12046.
[72] D.R. Clayburgh, T.A. Barrett, Y. Tang, J.B. Meddings, L.J. Van Eldik, D.M. Watterson,
L.L. Clarke, R.J. Mrsny, J.R. Turner, Epithelial myosin light chain kinase–dependent
barrier dysfunction mediates T cell activation–induced diarrhea in vivo, J. Clin. In-
vest. 115 (2005) 2702–2715.
[73] Y. Zolotarevsky, G. Hecht, A. Koutsouris, D.E. Gonzalez, C. Quan, J. Tom, R.J. Mrsny, J.R.
Turner, A membrane-permeant peptide that inhibits MLC kinase restores barrier func-
tion in in vitro models of intestinal disease, Gastroenterology 123 (2002) 163–172.
[74] F. Wang, W.V. Graham, Y. Wang, E.D. Witkowski, B.T. Schwarz, J.R. Turner, Interfer-
on-gamma; and Tumor Necrosis Factor-alpha; Synergize to Induce Intestinal Epi-
thelial Barrier Dysfunction by Up-Regulating Myosin Light Chain Kinase
Expression, Am. J. Pathol. 166 (2005) 409–419.
[75] D.R. Clayburgh, M.W. Musch, M. Leitges, Y.-X. Fu, J.R. Turner, Coordinated epithelial
NHE3 inhibition and barrier dysfunction are required for TNF-mediated diarrhea
in vivo, J. Clin. Invest. 116 (2006) 2682–2694.
[76] A. Casselbrant, E. Elias, L. Fändriks, V. Wallenius, Expression of tight-junction pro-
teins in human proximal small intestinal mucosa before and after Roux-en-Y gas-
tric bypass surgery, Surg. Obes. Relat. Dis. 11 (2015) 45–53.
[77] S. Zeissig, N. Bürgel, D. Günzel, J. Richter, J. Mankertz, U. Wahnschaffe, A.J. Kroesen,
M. Zeitz, M. Fromm, J.D. Schulzke, Changes in expression and distribution of
claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction
in active Crohn's disease, Gut 56 (2007) 61–72.
[78] N. Bürgel, C. Bojarski, J. Mankertz, M. Zeitz, M. Fromm, J.D. Schulzke, Mechanisms
of diarrhea in collagenous colitis, Gastroenterology 123 (2002) 433–443.
[79] M. Campbell, F. Hanrahan, O.L. Gobbo, M.E. Kelly, A.-S. Kiang, M.M. Humphries, A.T.
Nguyen, E. Ozaki, J. Keaney, C.W. Blau, Targeted suppression of claudin-5 decreases
cerebral oedema and improves cognitive outcome following traumatic brain inju-
ry, Nat. Commun. 3 (2012) 849.
[80] T. Lindmark, T. Nikkilä, P. Artursson, Mechanisms of absorption enhancement by
medium chain fatty acids in intestinal epithelial Caco-2 cell monolayers,
J. Pharmacol. Exp. Ther. 275 (1995) 958–964.
[81] S. Maher, R. Kennelly, V.A. Bzik, A.W. Baird, X. Wang, D. Winter, D.J. Brayden,
Evaluation of intestinal absorption enhancement and local mucosal toxicity of
two promoters. I. Studies in isolated rat and human colonic mucosae, Eur. J.
Pharm. Sci. 38 (2009) 291–300.
[82] T. Lindmark, J.D. Söderholm, G. Olaison, G. Alván, G. Ocklind, P. Artursson, Mecha-
nism of absorption enhancement in humans after rectal administration of ampicil-
lin in suppositories containing sodium caprate, Pharm. Res. 14 (1997) 930–935.
[83] M. Terrak, F. Kerff, K. Langsetmo, T. Tao, R. Dominguez, Structural basis of protein
phosphatase 1 regulation, Nature 429 (2004) 780–784.
[84] J.J. Berglund, M. Riegler, Y. Zolotarevsky, E. Wenzl, J.R. Turner, Regulation of human
jejunal transmucosal resistance and MLC phosphorylation by Na+-glucose co-
transport, Am. J. Physiol. Gastrointest. Liver Physiol. 281 (2001) G1487–G1493.
[85] L.M. Feighery, S.W. Cochrane, T. Quinn, A.W. Baird, D. O'Toole, S.-E. Owens, D.
O'Donoghue, R.J. Mrsny, D.J. Brayden, Myosin light chain kinase inhibition: correc-
tion of increased intestinal epithelial permeability in vitro, Pharm. Res. 25 (2008)
1377–1386.
[86] A.C. Kemper, R.D. Specian, Rat small intestinal mucins: a quantitative analysis,
Anat. Rec. 229 (1991) 219–226.
[87] T.D. Grant, R.D. Specian, Proliferation of goblet cells and vacuolated cells in the rab-
bit distal colon, Anat. Rec. 252 (1998) 41–48.
[88] O. Mace, B. Tehan, F. Marshall, Pharmacology and physiology of gastrointestinal
enteroendocrine cells, Pharmacol. Res. Perspect. 3 (2015).
[89] S.M. Karam, Lineage commitment and maturation of epithelial cells in the gut,
Front. Biosci. 4 (1999) D286–D298.
[90] A.M. Mowat, W.W. Agace, Regional specialization within the intestinal immune
system, Nat. Rev. Immunol. 14 (2014) 667–685.
[91] J. Söderholm, The intestinal barrier and its regulation by neuroimmune factors,
Neurogastroenterol. Motil. 22 (2010) 718–733.
[92] R.L. Owen, Sequential uptake of horseradish peroxidase by lymphoid follicle epi-
thelium of Peyer's patches in the normal unobstructed mouse intestine: an ultra-
structural study, Gastroenterology 72 (1977) 440–451.
[93] M.R. Neutra, A. Frey, J.-P. Kraehenbuhl, Epithelial M cells: gateways for mucosal in-
fection and immunization, Cell 86 (1996) 345–348.
[94] A. Ermund, J.K. Gustafsson, G.C. Hansson, Å.V. Keita, Mucus properties and goblet
cell quantiﬁcation in mouse, rat and human ileal Peyer's patches, PLoS One 8
(2013), e83688.
274 P. Lundquist, P. Artursson / Advanced Drug Delivery Reviews 106 (2016) 256–276[95] J.H. Niess, H.C. Reinecker, Dendritic cells in the recognition of intestinal microbiota,
Cell. Microbiol. 8 (2006) 558–564.
[96] H.F. Helander, L. Fändriks, Surface area of the digestive tract—revisited, Scand. J.
Gastroenterol. 49 (2014) 681–689.
[97] W.M. Miner-Williams, B.R. Stevens, P.J. Moughan, Are intact peptides absorbed
from the healthy gut in the adult human? Nutr. Res. Rev. 27 (2014) 308–329.
[98] D.E. Smith, B. Clémençon, M.A. Hediger, Proton-coupled oligopeptide transporter
family SLC15: physiological, pharmacological and pathological implications, Mol.
Asp. Med. 34 (2013) 323–336.
[99] E. Vives, P. Brodin, B. Lebleu, A truncated HIV-1 Tat protein basic domain rapidly
translocates through the plasma membrane and accumulates in the cell nucleus,
J. Biol. Chem. 272 (1997) 16010–16017.
[100] W.B. Kauffman, T. Fuselier, J. He, W.C. Wimley, Mechanismmatters: a taxonomy of
cell penetrating peptides, Trends Biochem. Sci. 40 (2015) 749–764.
[101] E. Dupont, A. Prochiantz, A. Joliot, Penetratin story: an overview, Cell-Penetrating
Pept. Methods Protoc. (2015) 29–37.
[102] J.R. Marks, J. Placone, K. Hristova, W.C. Wimley, Spontaneous membrane-
translocating peptides by orthogonal high-throughput screening, J. Am. Chem.
Soc. 133 (2011) 8995–9004.
[103] M. Kristensen, H.M. Nielsen, Cell-penetrating peptides as carriers for oral delivery
of biopharmaceuticals, Basic Clin. Pharmacol. Toxicol. 118 (2016) 99–106.
[104] S. Zhu, S. Chen, Y. Gao, F. Guo, F. Li, B. Xie, J. Zhou, H. Zhong, Enhanced oral bioavail-
ability of insulin using PLGA nanoparticles co-modiﬁed with cell-penetrating pep-
tides and Engrailed secretion peptide (Sec), Drug Deliv. (2015) 1–12.
[105] E. Dupont, A. Prochiantz, A. Joliot, Identiﬁcation of a signal peptide for unconven-
tional secretion, J. Biol. Chem. 282 (2007) 8994–9000.
[106] J.E. Preston, N.J. Abbott, D.J. Begley, Chapter ﬁve-transcytosis of macromolecules at
the blood–brain barrier, Adv. Pharmacol. 71 (2014) 147–163.
[107] G.J. Doherty, H.T. McMahon, Mechanisms of endocytosis, Annu. Rev. Biochem. 78
(2009) 857–902.
[108] J.T. Sockolosky, M.R. Tiffany, F.C. Szoka, Engineering neonatal Fc receptor-mediated
recycling and transcytosis in recombinant proteins by short terminal peptide ex-
tensions, Proc. Natl. Acad. Sci. 109 (2012) 16095–16100.
[109] E.M. Pridgen, F. Alexis, T.T. Kuo, E. Levy-Nissenbaum, R. Karnik, R.S. Blumberg, R.
Langer, O.C. Farokhzad, Transepithelial transport of Fc-targeted nanoparticles by
the neonatal fc receptor for oral delivery, Sci. Transl. Med. 5 (2013) 213ra167.
[110] R. Rojas, G. Apodaca, Immunoglobulin transport across polarized epithelial cells,
Nat. Rev. Mol. Cell Biol. 3 (2002) 944–956.
[111] J.S. Wolf, G. Li, A. Varadhachary, K. Petrak, M. Schneyer, D. Li, J. Ongkasuwan, X.
Zhang, R.J. Taylor, S.E. Strome, Oral lactoferrin results in T cell-dependent tumor in-
hibition of head and neck squamous cell carcinoma in vivo, Clin. Cancer Res. 13
(2007) 1601–1610.
[112] G. Mahidhara, R.K. Kanwar, K. Roy, J.R. Kanwar, Oral administration of iron-
saturated bovine lactoferrin-loaded ceramic nanocapsules for breast cancer thera-
py and inﬂuence on iron and calcium metabolism, Int. J. Nanomedicine 10 (2015)
4081.
[113] C.H. Fazen, D. Valentin, T.J. Fairchild, R.P. Doyle, Oral delivery of the appetite sup-
pressing peptide hPYY (3–36) through the vitamin B12 uptake pathway, J. Med.
Chem. 54 (2011) 8707–8711.
[114] D.H. Alpers, G. Russell-Jones, Gastric intrinsic factor: the gastric and small intestinal
stages of cobalamin absorption. A personal journey, Biochimie 95 (2013) 989–994.
[115] A. Verma, S. Sharma, P.K. Gupta, A. Singh, B.V. Teja, P. Dwivedi, G.K. Gupta, R.
Trivedi, P.R. Mishra, Vitamin B12 functionalized layer by layer calcium phosphate
nanoparticles: a mucoadhesive and pH responsive carrier for improved oral deliv-
ery of insulin, Acta Biomater. (2015).
[116] K.B. Chalasani, G.J. Russell-Jones, A.K. Jain, P.V. Diwan, S.K. Jain, Effective oral deliv-
ery of insulin in animal models using vitamin B12-coated dextran nanoparticles,
J. Control. Release 122 (2007) 141–150.
[117] M. Cohen, D. Kitsberg, S. Tsytkin,M. Shulman, B. Aroeti, Y. Nahmias, Live imaging of
GLUT2 glucose-dependent trafﬁcking and its inhibition in polarized epithelial
cysts, Open Biol. 4 (2014) 140091.
[118] C. Guan, J. Ji, C. Jin, G. Wang, X. Li, W. Guan, Expression of cholera toxin B subunit –
lumbrokinase in edible sunﬂower seeds – the use of transmucosal carrier to en-
hance its fusion protein's effect on protection of rats and mice against thrombosis,
Biotechnol. Prog. 30 (2014) 1029–1039.
[119] N. Kohli, D.R. Westerveld, A.C. Ayache, A. Verma, P. Shil, T. Prasad, P. Zhu, S.L. Chan,
Q. Li, H. Daniell, Oral delivery of bioencapsulated proteins across blood–brain and
blood–retinal barriers, Mol. Ther. 22 (2014) 535–546.
[120] K.L. Noakes, H.T. Teisserenc, J.M. Lord, P. Dunbar, V. Cerundolo, L.M. Roberts,
Exploiting retrograde transport of Shiga-like toxin 1 for the delivery of exog-
enous antigens into the MHC class I presentation pathway, FEBS Lett. 453
(1999) 95–99.
[121] J.-H. Ryou, Y.-K. Sohn, D.-E. Hwang, H.-S. Kim, Shiga-like toxin-based high-
efﬁciency and receptor-speciﬁc intracellular delivery system for a protein,
Biochem. Biophys. Res. Commun. 464 (2015) 1282–1289.
[122] B.P. Hurley, M. Jacewicz, C. Thorpe, L.L. Lincicome, A.J. King, G.T. Keusch, D.W.
Acheson, Shiga toxins 1 and 2 translocate differently across polarized intestinal ep-
ithelial cells, Infect. Immun. 67 (1999) 6670–6677.
[123] Y.M. te Welscher, D.J.-F. Chinnapen, L. Kaoutzani, R.J. Mrsny, W.I. Lencer,
Unsaturated glycoceramides as molecular carriers for mucosal drug delivery of
GLP-1, J. Control. Release 175 (2014) 72–78.
[124] G. Battogtokh, Y.T. Ko, Self-assembled chitosan-ceramide nanoparticle for en-
hanced oral delivery of paclitaxel, Pharm. Res. 31 (2014) 3019–3030.
[125] N. Wang, T. Wang, M. Zhang, R. Chen, R. Niu, Y. Deng, Mannose derivative and lipid
A dually decorated cationic liposomes as an effective cold chain free oral mucosal
vaccine adjuvant-delivery system, Eur. J. Pharm. Biopharm. 88 (2014) 194–206.[126] W. Situ, X. Li, J. Liu, L. Chen, Preparation and characterization of glycoprotein-resis-
tant starch complex as a coating material for oral bioadhesive microparticles for
colon-targeted polypeptide delivery, J. Agric. Food Chem. 63 (2015) 4138–4147.
[127] S. Mayor, R.G. Parton, J.G. Donaldson, Clathrin-independent pathways of endocyto-
sis, Cold Spring Harb. Perspect. Biol. 6 (2014) a016758.
[128] B. Ritter, S. Murphy, H. Dokainish, M. Girard, M.V. Gudheti, G. Kozlov, M. Halin, J.
Philie, E.M. Jorgensen, K. Gehring, NECAP 1 regulates AP-2 interactions to control
vesicle size, number, and cargo during clathrin-mediated endocytosis, PLoS Biol.
11 (2013), e1001670.
[129] S.E. Miller, S. Mathiasen, N.A. Bright, F. Pierre, B.T. Kelly, N. Kladt, A. Schauss, C.J.
Merriﬁeld, D. Stamou, S. Höning, CALM regulates clathrin-coated vesicle size and
maturation by directly sensing and driving membrane curvature, Dev. Cell 33
(2015) 163–175.
[130] L. Pelkmans, A. Helenius, Endocytosis via caveolae, Trafﬁc 3 (2002) 311–320.
[131] S. Falcone, E. Cocucci, P. Podini, T. Kirchhausen, E. Clementi, J. Meldolesi,
Macropinocytosis: regulated coordination of endocytic and exocytic membrane
trafﬁc events, J. Cell Sci. 119 (2006) 4758–4769.
[132] D. Corda, C.H. Carcedo, M. Bonazzi, A. Luini, S. Spano, Molecular aspects of mem-
brane ﬁssion in the secretory pathway, Cell. Mol. Life Sci. 59 (2002) 1819–1832.
[133] G.J. Praefcke, H.T. McMahon, The dynamin superfamily: universal membrane
tubulation and ﬁssion molecules? Nat. Rev. Mol. Cell Biol. 5 (2004) 133–147.
[134] A. des Rieux, V. Pourcelle, P.D. Cani, J. Marchand-Brynaert, V. Préat, Targeted nano-
particles with novel non-peptidic ligands for oral delivery, Adv. Drug Deliv. Rev. 65
(2013) 833–844.
[135] X. Zhang, W. Wu, Ligand-mediated active targeting for enhanced oral absorption,
Drug Discov. Today 19 (2014) 898–904.
[136] R. Fowler, D. Vllasaliu, F.F. Trillo, M. Garnett, C. Alexander, H. Horsley, B. Smith, I.
Whitcombe, M. Eaton, S. Stolnik, Nanoparticle transport in epithelial cells: path-
way switching through bioconjugation, Small 9 (2013) 3282–3294.
[137] A. des Rieux, E.G. Ragnarsson, E. Gullberg, V. Préat, Y.-J. Schneider, P. Artursson,
Transport of nanoparticles across an in vitro model of the human intestinal follicle
associated epithelium, Eur. J. Pharm. Sci. 25 (2005) 455–465.
[138] E. Gullberg, M. Leonard, J. Karlsson, A.M. Hopkins, D. Brayden, A.W. Baird, P.
Artursson, Expression of speciﬁc markers and particle transport in a new human
intestinal M-cell model, Biochem. Biophys. Res. Commun. 279 (2000) 808–813.
[139] T. Kirchhausen, E. Macia, H.E. Pelish, Use of dynasore, the small molecule inhibitor
of dynamin, in the regulation of endocytosis, Methods Enzymol. 438 (2008) 77–93.
[140] E. Macia, M. Ehrlich, R. Massol, E. Boucrot, C. Brunner, T. Kirchhausen, Dynasore, a
cell-permeable inhibitor of dynamin, Dev. Cell 10 (2006) 839–850.
[141] A.I. Ivanov, Pharmacological inhibition of endocytic pathways: is it speciﬁc enough
to be useful? Exocytosis Endocytosis (2008) 15–33.
[142] D. Vercauteren, R.E. Vandenbroucke, A.T. Jones, J. Rejman, J. Demeester, S.C. De
Smedt, N.N. Sanders, K. Braeckmans, The use of inhibitors to study endocytic path-
ways of gene carriers: optimization and pitfalls, Mol. Ther. 18 (2010) 561–569.
[143] H. Stenmark, Rab GTPases as coordinators of vesicle trafﬁc, Nat. Rev. Mol. Cell Biol.
10 (2009) 513–525.
[144] A.H. Hutagalung, P.J. Novick, Role of Rab GTPases in membrane trafﬁc and cell
physiology, Physiol. Rev. 91 (2011) 119–149.
[145] E. Rodriguez-Boulan, I.G. Macara, Organization and execution of the epithelial po-
larity programme, Nat. Rev. Mol. Cell Biol. 15 (2014) 225–242.
[146] W. Hunziker, P.J. Peters, Rab17 localizes to recycling endosomes and regulates
receptor-mediated transcytosis in epithelial cells, J. Biol. Chem. 273 (1998)
15734–15741.
[147] J.E. Casanova, X. Wang, R. Kumar, S.G. Bhartur, J. Navarre, J.E. Woodrum, Y.
Altschuler, G.S. Ray, J.R. Goldenring, Association of Rab25 and Rab11a with the api-
cal recycling system of polarized Madin-Darby canine kidney cells, Mol. Biol. Cell
10 (1999) 47–61.
[148] D.R. Sheff, E.A. Daro, M. Hull, I. Mellman, The receptor recycling pathway contains
two distinct populations of early endosomes with different sorting functions, J. Cell
Biol. 145 (1999) 123–139.
[149] P. Sandin, L.W. Fitzpatrick, J.C. Simpson, K.A. Dawson, High-speed imaging of Rab
family small GTPases reveals rare events in nanoparticle trafﬁcking in living cells,
ACS Nano 6 (2012) 1513–1521.
[150] O. Ullrich, S. Reinsch, S. Urbé, M. Zerial, R.G. Parton, Rab11 regulates recycling
through the pericentriolar recycling endosome, J. Cell Biol. 135 (1996) 913–924.
[151] M.E. Taub, W.C. Shen, Polarity in the transcytotic processing of apical and basal
membrane-bound peroxidase-polylysine conjugates in MDCK cells, J. Cell. Physiol.
150 (1992) 283–290.
[152] W. He, M.S. Ladinsky, K.E. Huey-Tubman, G.J. Jensen, J.R. McIntosh, P.J. Björkman,
FcRn-mediated antibody transport across epithelial cells revealed by electron to-
mography, Nature 455 (2008) 542–546.
[153] M.E. Taub, W.-C. Shen, Regulation of pathways within cultured epithelial cells for
the transcytosis of a basal membrane-bound peroxidase-polylysine conjugate,
J. Cell Sci. 106 (1993) 1313–1322.
[154] K. Prydz, S.H. Hansen, K. Sandvig, B. van Deurs, Effects of brefeldin A on endocyto-
sis, transcytosis and transport to the Golgi complex in polarized MDCK cells, J. Cell
Biol. 119 (1992) 259–272.
[155] P.G. Cammisotto, M. Bendayan, A. Sané, M. Dominguez, C. Garofalo, E. Levy,
Receptor-mediated transcytosis of leptin through human intestinal cells in vitro,
Int. J. Cell Biol. 2010 (2010).
[156] S.J., S.J. Mansour, X.H. Zhao, J. Giordano, S.W. Scherer, P. Melançon, p200 ARF-GEP1:
a Golgi-localized guanine nucleotide exchange protein whose Sec7 domain is
targeted by the drug brefeldin A, Proc. Natl. Acad. Sci. U. S. A. 96 (1999)
7968–7973.
[157] J.G. Donaldson, D. Finazzi, R.D. Klausner, Brefeldin A Inhibits Golgi Membrane-
catalysed Exchange of Guanine Nucleotide onto ARF Protein, 1992.
275P. Lundquist, P. Artursson / Advanced Drug Delivery Reviews 106 (2016) 256–276[158] E.B. Cluett, S.A. Wood, M. Banta, W.J. Brown, Tubulation of Golgi membranes
in vivo and in vitro in the absence of brefeldin A, J. Cell Biol. 120 (1993) 15–24.
[159] K. Takashima, A. Saitoh, S. Hirose, W. Nakai, Y. Kondo, Y. Takasu, H. Kakeya, H.-W.
Shin, K. Nakayama, GBF1-Arf-COPI-ArfGAP-mediated Golgi-to-ER transport in-
volved in regulation of lipid homeostasis, Cell Struct. Funct. 36 (2011) 223–235.
[160] G. Strous, P. Van Kerkhof, G. Van Meer, S. Rijnboutt, W. Stoorvogel, Differential ef-
fects of brefeldin A on transport of secretory and lysosomal proteins, J. Biol. Chem.
268 (1993) 2341–2347.
[161] J. Scheel, R. Pepperkok, M. Lowe, G. Grifﬁths, T.E. Kreis, Dissociation of coatomer
from membranes is required for brefeldin A-induced transfer of Golgi enzymes
to the endoplasmic reticulum, J. Cell Biol. 137 (1997) 319–333.
[162] R. Guidi, L. Levi, S.F. Rouf, S. Puiac, M. Rhen, T. Frisan, Salmonella enterica delivers
its genotoxin through outer membrane vesicles secreted from infected cells, Cell.
Microbiol. 15 (2013) 2034–2050.
[163] A. El Baya, R. Linnemann, L. von Olleschik-Elbheim, H. Robenek, M. Schmidt,
Endocytosis and retrograde transport of pertussis toxin to the Golgi complex as
a prerequisite for cellular intoxication, Eur. J. Cell Biol. 73 (1997) 40–48.
[164] D.J.-F. Chinnapen, H. Chinnapen, D. Saslowsky, W.I. Lencer, Rafting with cholera
toxin: endocytosis and trafﬁcking from plasma membrane to ER, FEMS Microbiol.
Lett. 266 (2007) 129–137.
[165] W. Nakai, Y. Kondo, A. Saitoh, T. Naito, K. Nakayama, H.-W. Shin, ARF1 and ARF4
regulate recycling endosomal morphology and retrograde transport from
endosomes to the Golgi apparatus, Mol. Biol. Cell 24 (2013) 2570–2581.
[166] T. Su, D.M. Bryant, F. Luton, M. Vergés, S.M. Ulrich, K.C. Hansen, A. Datta, D.J.
Eastburn, A.L. Burlingame, K.M. Shokat, A kinase cascade leading to Rab11-FIP5
controls transcytosis of the polymeric immunoglobulin receptor, Nat. Cell Biol.
12 (2010) 1143–1153.
[167] K. Baker, S.-W. Qiao, T. Kuo, K. Kobayashi, M. Yoshida, W.I. Lencer, R.S. Blumberg,
Immune and non-immune functions of the (not so) neonatal Fc receptor, FcRn,
Semin. Immunopathol. 31 (2009) 223–236.
[168] S. Tzaban, R.H. Massol, E. Yen, W. Hamman, S.R. Frank, L.A. Lapierre, S.H. Hansen,
J.R. Goldenring, R.S. Blumberg, W.I. Lencer, The recycling and transcytotic path-
ways for IgG transport by FcRn are distinct and display an inherent polarity,
J. Cell Biol. 185 (2009) 673–684.
[169] B.L. Dickinson, K. Badizadegan, Z. Wu, J.C. Ahouse, X. Zhu, N.E. Simister, R.S.
Blumberg, W.I. Lencer, Bidirectional FcRn-dependent IgG transport in a polarized
human intestinal epithelial cell line, J. Clin. Invest. 104 (1999) 903–911.
[170] Z. Wu, N.E. Simister, Tryptophan- and dileucine-based endocytosis signals in the
neonatal Fc receptor, J. Biol. Chem. 276 (2001) 5240–5247.
[171] O. Pabst, A. Mowat, Oral tolerance to food protein, Mucosal Immunol. 5 (2012)
232–239.
[172] T. Rath, T.T. Kuo, K. Baker, S.-W. Qiao, K. Kobayashi, M. Yoshida, D. Roopenian, E.
Fiebiger, W.I. Lencer, R.S. Blumberg, The immunologic functions of the neonatal
Fc receptor for IgG, J. Clin. Immunol. 33 (2013) 9–17.
[173] A.J. Bitonti, J.A. Dumont, Pulmonary administration of therapeutic proteins using
an immunoglobulin transport pathway, Adv. Drug Deliv. Rev. 58 (2006)
1106–1118.
[174] J.A. Dumont, A.J. Bitonti, D. Clark, S. Evans, M. Pickford, S.P. Newman, Delivery of an
erythropoietin-Fc fusion protein by inhalation in humans through an immuno-
globulin transport pathway, J. Aerosol Med. 18 (2005) 294–303.
[175] D. Vllasaliu, C. Alexander, M. Garnett, M. Eaton, S. Stolnik, Fc-mediated transport of
nanoparticles across airway epithelial cell layers, J. Control. Release 158 (2012)
479–486.
[176] J.C. Fyfe, M. Madsen, P. Højrup, E.I. Christensen, S.M. Tanner, A. de la Chapelle, Q. He,
S.K. Moestrup, The functional cobalamin (vitamin B12)-intrinsic factor receptor is a
novel complex of cubilin and amnionless, Blood 103 (2004) 1573–1579.
[177] G.A. Pedersen, S. Chakraborty, A.L. Steinhauser, L.M. Traub, M. Madsen, AMN di-
rects endocytosis of the intrinsic factor-vitamin B12 receptor cubam by engaging
ARH or Dab2, Trafﬁc 11 (2010) 706–720.
[178] D.H. Alpers, Absorption and blood/cellular transport of folate and cobalamin: phar-
macokinetic and physiological considerations, Biochimie (2015).
[179] L.H. Allen, How common is vitamin B-12 deﬁciency? Am. J. Clin. Nutr. 89 (2009)
693S–696S.
[180] H. He, P. Wang, C. Cai, R. Yang, X. Tang, VB 12-coated Gel-Core-SLN containing in-
sulin: another way to improve oral absorption, Int. J. Pharm. 493 (2015) 451–459.
[181] U. Wrackmeyer, G.H. Hansen, T. Seya, E.M. Danielsen, Intelectin: a novel lipid raft-
associated protein in the enterocyte brush border, Biochemistry 45 (2006)
9188–9197.
[182] B. Lönnerdal, R. Jiang, X. Du, Bovine lactoferrin can be taken up by the human in-
testinal lactoferrin receptor and exert bioactivities, J. Pediatr. Gastroenterol. Nutr.
53 (2011) 606–614.
[183] R. Jiang, V. Lopez, S.L. Kelleher, B. Lönnerdal, Apo-and holo-lactoferrin are both in-
ternalized by lactoferrin receptor via clathrin-mediated endocytosis but differen-
tially affect ERK-signaling and cell proliferation in caco-2 cells, J. Cell. Physiol.
226 (2011) 3022–3031.
[184] R. Prades, B. Oller-Salvia, S.M. Schwarzmaier, J. Selva, M. Moros, M. Balbi, V. Grazú,
J.M. de La Fuente, G. Egea, N. Plesnila, Applying the retro-enantio approach to ob-
tain a peptide capable of overcoming the blood–brain barrier, Angew. Chem. Int.
Ed. 54 (2015) 3967–3972.
[185] S. Gulec, G.J. Anderson, J.F. Collins, Mechanistic and regulatory aspects of intestinal
iron absorption, Am. J. Physiol. Gastrointest. Liver Physiol. 307 (2014) G397–G409.
[186] W.J. Grifﬁths, T.M. Cox, Co-localization of the mammalian hemochromatosis gene
product (HFE) and a newly identiﬁed transferrin receptor (TfR2) in intestinal tis-
sue and cells, J. Histochem. Cytochem. 51 (2003) 613–623.
[187] W. Zheng, J. Kollmeyer, H. Symolon, A. Momin, E. Munter, E. Wang, S. Kelly, J.C.
Allegood, Y. Liu, Q. Peng, Ceramides and other bioactive sphingolipid backbonesin health and disease: lipidomic analysis, metabolism and roles in membrane
structure, dynamics, signaling and autophagy, Biochim. Biophys. Acta Biomembr.
1758 (2006) 1864–1884.
[188] Y.H. Zeidan, Y.A. Hannun, Translational aspects of sphingolipid metabolism, Trends
Mol. Med. 13 (2007) 327–336.
[189] K. Hanada, K. Kumagai, S. Yasuda, Y. Miura, M. Kawano, M. Fukasawa, M. Nishijima,
Molecular machinery for non-vesicular trafﬁcking of ceramide, Nature 426 (2003)
803–809.
[190] D.J.-F. Chinnapen, W.-T. Hsieh, Y.M. te Welscher, D.E. Saslowsky, L. Kaoutzani, E.
Brandsma, L. D'Auria, H. Park, J.S. Wagner, K.R. Drake, Lipid sorting by ceramide
structure from plasma membrane to ER for the cholera toxin receptor ganglioside
GM1, Dev. Cell 23 (2012) 573–586.
[191] D.E. Saslowsky, Y.M. te Welscher, D.J.-F. Chinnapen, J.S. Wagner, J. Wan, E. Kern,
W.I. Lencer, Ganglioside GM1-mediated transcytosis of cholera toxin bypasses
the retrograde pathway and depends on the structure of the ceramide domain,
J. Biol. Chem. 288 (2013) 25804–25809.
[192] J.J. Powell, E. Thomas-McKay, V. Thoree, J. Robertson, R.E. Hewitt, J.N. Skepper, A.
Brown, J.C. Hernandez-Garrido, P.A. Midgley, I. Gomez-Morilla, An endogenous
nanomineral chaperones luminal antigen and peptidoglycan to intestinal immune
cells, Nat. Nanotechnol. (2015).
[193] J.D. Söderholm, Gut immunology: nanoparticles ferry gut antigens, Nat.
Nanotechnol. 10 (2015) 298–299.
[194] M.R. Neutra, N.J. Mantis, J.-P. Kraehenbuhl, Collaboration of epithelial cells with or-
ganized mucosal lymphoid tissues, Nat. Immunol. 2 (2001) 1004–1009.
[195] C. Wallon, Y. Braaf, M. Wolving, G. Olaison, J.D. Söderholm, Endoscopic biopsies in
Ussing chambers evaluated for studies of macromolecular permeability in the
human colon, Scand. J. Gastroenterol. 40 (2005) 586–595.
[196] M. Foltz, A. Cerstiaens, A. van Meensel, R. Mols, P.C. van der Pijl, G.S. Duchateau, P.
Augustijns, The angiotensin converting enzyme inhibitory tripeptides Ile-Pro-Pro
and Val-Pro-Pro show increasing permeabilities with increasing physiological rel-
evance of absorption models, Peptides 29 (2008) 1312–1320.
[197] H.J. Van Kruiningen, A.B. West, B.J. Freda, K.A. Holmes, Distribution of Peyer's
patches in the distal ileum, Inﬂamm. Bowel Dis. 8 (2002) 180–185.
[198] H. Van Kruiningen, L. Ganley, B. Freda, The role of Peyer's patches in the age-related
incidence of Crohn's disease, J. Clin. Gastroenterol. 25 (1997) 470–475.
[199] P.C. Tyrer, A.R. Foxwell, J.M. Kyd, D.C. Otczyk, A.W. Cripps, Receptor mediated
targeting of M-cells, Vaccine 25 (2007) 3204–3209.
[200] J.-P. Kraehenbuhl, M.R. Neutra, Epithelial M cells: differentiation and function,
Annu. Rev. Cell Dev. Biol. 16 (2000) 301–332.
[201] E. Gullberg, Å.V. Keita, Y.S. Sa'ad, M. Andersson, K.D. Caldwell, J.D. Söderholm, P.
Artursson, Identiﬁcation of cell adhesion molecules in the human follicle-
associated epithelium that improve nanoparticle uptake into the Peyer's patches,
J. Pharmacol. Exp. Ther. 319 (2006) 632–639.
[202] J. Soni, A.W. Baird, L.M. O'Brien, M. McElroy, J.J. Callanan, H.F. Bassett, D.
Campion, D.J. Brayden, Rat, ovine and bovine Peyer's patches mounted in hor-
izontal diffusion chambers display sampling function, J. Control. Release 115
(2006) 68–77.
[203] N.N. Parayath, H. Nehoff, P. Mueller, S. Taurin, K. Greish, Styrene maleic acid mi-
celles as a nanocarrier system for oral anticancer drug delivery—dual uptake
through enterocytes and M-cells, Int. J. Nanomedicine 10 (2015) 4653.
[204] C. Damgé, M. Aprahamian, W. Humbert, M. Pinget, Ileal uptake of
polyalkylcyanoacrylate nanocapsules in the rat, J. Pharm. Pharmacol. 52 (2000)
1049–1056.
[205] J. Pappo, T. Ermak, Uptake and translocation of ﬂuorescent latex particles by rabbit
Peyer's patch follicle epithelium: a quantitative model for M cell uptake, Clin. Exp.
Immunol. 76 (1989) 144.
[206] M. De Jesus, G.R. Ostroff, S.M. Levitz, T.R. Bartling, N.J. Mantis, A population of
Langerin-positive dendritic cells in murine Peyer's patches involved in sampling
β-glucan microparticles, PLoS One 9 (2014), e91002.
[207] V.K. Shreedhar, B.L. Kelsall, M.R. Neutra, Cholera toxin induces migration of den-
dritic cells from the subepithelial dome region to T- and B-cell areas of Peyer's
patches, Infect. Immun. 71 (2003) 504–509.
[208] E. Lawless, B.T. Grifﬁn, A. O'Mahony, C.M. O'Driscoll, Exploring the impact of drug
properties on the extent of intestinal lymphatic transport—in vitro and in vivo
studies, Pharm. Res. 32 (2015) 1817–1829.
[209] H. YOSHIKAWA, K. TAKADA, S. MURANISHI, Molecular weight dependence of
permselectivity to rat small intestinal blood-lymph barrier for exogenous macro-
molecules absorbed from lumen, J. Pharmacobio-Dyn. 7 (1984) 1–6.
[210] D.A. Rothenﬂuh, H. Bermudez, C.P. O'Neil, J.A. Hubbell, Biofunctional polymer
nanoparticles for intra-articular targeting and retention in cartilage, Nat. Mater. 7
(2008) 248–254.
[211] P.B. Patil, P.B. Chougule, V.K. Kumar, S. Almström, H. Bäckdahl, D. Banerjee, G.
Herlenius, M. Olausson, S. Sumitran-Holgersson, Recellularization of acellular
human small intestine using bone marrow stem cells, Stem Cells Transl. Med.
(2013), http://dx.doi.org/10.5966/sctm.2012-0108.
[212] C.A. Barnes, J. Brison, R. Michel, B.N. Brown, D.G. Castner, S.F. Badylak, B.D. Ratner,
The surfacemolecular functionality of decellularized extracellularmatrices, Bioma-
terials 32 (2011) 137–143.
[213] P. Artursson, Epithelial transport of drugs in cell culture. I: a model for studying the
passive diffusion of drugs over intestinal absorbtive (Caco-2) cells, J. Pharm. Sci. 79
(1990) 476–482.
[214] G. Wilson, I.F. Hassan, C.J. Dix, I. Williamson, R. Shah, M. Mackay, P. Artursson,
Transport and permeability properties of human Caco-2 cells: an in vitro model
of the intestinal epithelial cell barrier, J. Control. Release 11 (1990) 25–40.
[215] A.R. Hilgers, R.A. Conradi, P.S. Burton, Caco-2 cell monolayers as a model for drug
transport across the intestinal mucosa, Pharm. Res. 7 (1990) 902–910.
276 P. Lundquist, P. Artursson / Advanced Drug Delivery Reviews 106 (2016) 256–276[216] I.J. Hidalgo, T.J. Raub, R.T. Borchardt, Characterization of the human colon carcino-
ma cell line (Caco-2) as a model system for intestinal epithelial permeability, Gas-
troenterology 96 (1989) 736–749.
[217] I. Hubatsch, E.G. Ragnarsson, P. Artursson, Determination of drug permeability and
prediction of drug absorption in Caco-2 monolayers, Nat. Protoc. 2 (2007)
2111–2119.
[218] S. Tavelin, J. Gråsjö, J. Taipalensuu, G. Ocklind, P. Artursson, Applications of epithe-
lial cell culture in studies of drug transport, Epithelial Cell Cult. Protoc. (2002)
233–272.
[219] A.Wikman, J. Karlsson, I. Carlstedt, P. Artursson, A drug absorption model based on
the mucus layer producing human intestinal goblet cell line HT29-H, Pharm. Res.
10 (1993) 843–852.
[220] J. Karlsson, A. Wikman, P. Artursson, The mucus layer as a barrier to drug absorp-
tion inmonolayers of human intestinal epithelial HT29-H goblet cells, Int. J. Pharm.
99 (1993) 209–218.
[221] C. Hilgendorf, H. Spahn-Langguth, C.G. Regårdh, E. Lipka, G.L. Amidon, P. Langguth,
Caco-2 versus caco-2/HT29-MTX co-cultured cell lines: permeabilities via diffu-
sion, inside-and outside-directed carrier-mediated transport, J. Pharm. Sci. 89
(2000) 63–75.
[222] A. Wikman-Larhed, P. Artursson, Co-cultures of human intestinal goblet (HT29-H)
and absorptive (Caco-2) cells for studies of drug and peptide absorption, Eur. J.
Pharm. Sci. 3 (1995) 171–183.
[223] C. Schimpel, B. Teubl, M. Absenger, C. Meindl, E. Fröhlich, G. Leitinger, A. Zimmer, E.
Roblegg, Development of an advanced intestinal in vitro triple culture permeability
model to study transport of nanoparticles, Mol. Pharm. 11 (2014) 808–818.
[224] I. Behrens, P. Stenberg, P. Artursson, T. Kissel, Transport of lipophilic drug mole-
cules in a new mucus-secreting cell culture model based on HT29-MTX cells,
Pharm. Res. 18 (2001) 1138–1145.
[225] S. Keely, A. Rullay, C. Wilson, A. Carmichael, S. Carrington, A. Corﬁeld, D.M.
Haddleton, D.J. Brayden, In vitro and ex vivo intestinal tissue models to measure
mucoadhesion of poly (methacrylate) and N-trimethylated chitosan polymers,
Pharm. Res. 22 (2005) 38–49.
[226] J. Grießinger, S. Dünnhaupt, B. Cattoz, P. Grifﬁths, S. Oh, S.B.i. Gómez, M. Wilcox, J.
Pearson, M. Gumbleton, M. Abdulkarim, Methods to determine the interactions of
micro-and nanoparticles with mucus, Eur. J. Pharm. Biopharm. 96 (2015) 464–476.
[227] A.F. Quest, J.L. Gutierrez-Pajares, V.A. Torres, Caveolin-1: an ambiguous partner in
cell signalling and cancer, J. Cell. Mol. Med. 12 (2008) 1130–1150.
[228] S. Hehlgans, N. Cordes, Caveolin-1: an essential modulator of cancer cell radio-and
chemoresistance, Am. J. Cancer Res. 1 (2011) 521–530.
[229] N. Dasgupta, B.K. Thakur, A. Ta, S. Das, Caveolin-1 is transcribed from a
hypermethylated promoter to mediate colonocyte differentiation and apoptosis,
Exp. Cell Res. 334 (2015) 323–336.
[230] P. Ilina, S. Partti, J. Niklander, M. Ruponen, Y.-R. Lou, M. Yliperttula, Effect of differ-
entiation on endocytic proﬁles of endothelial and epithelial cell culture models,
Exp. Cell Res. 332 (2015) 89–101.
[231] S. Kernéis, A. Bogdanova, J.-P. Kraehenbuhl, E. Pringault, Conversion by Peyer's
patch lymphocytes of human enterocytes into M cells that transport bacteria,
Science 277 (1997) 949–952.
[232] M. Miyake, E. Ragnarsson, D. Nakai, P. Artursson, The pro-inﬂammatory cytokine
interleukin-6 regulates nanoparticle transport across model follicle-associated ep-
ithelium cells, J. Pharm. Sci. (2016).
[233] E.G. Ragnarsson, I. Schoultz, E. Gullberg, A.H. Carlsson, F. Tafazoli, M. Lerm, K.-E.
Magnusson, J.D. Söderholm, P. Artursson, Yersinia pseudotuberculosis induces
transcytosis of nanoparticles across human intestinal villus epithelium via
invasin-dependent macropinocytosis, Lab. Investig. 88 (2008) 1215–1226.
[234] K. Dharmsathaphorn, S. Carlson, Structural analysis of a human intestinal epithelial
cell line, Gastroenterology 92 (1987) 1133–1145.
[235] S. Tavelin, V. Milovic, G. Ocklind, S. Olsson, P. Artursson, A conditionally immortal-
ized epithelial cell line for studies of intestinal drug transport, J. Pharmacol. Exp.
Ther. 290 (1999) 1212–1221.
[236] E. Paul, J. Hochman, A. Quaroni, Conditionally immortalized intestinal epithelial
cells: novel approach for study of differentiated enterocytes, Am. J. Phys. Cell
Phys. 265 (1993) C266–C278.
[237] T. Takenaka, N. Harada, J. Kuze, M. Chiba, T. Iwao, T. Matsunaga, Human small in-
testinal epithelial cells differentiated from adult intestinal stem cells as a novel sys-
tem for predicting oral drug absorption in humans, Drug Metab. Dispos. 42 (2014)
1947–1954.
[238] T. Takenaka, N. Harada, J. Kuze, M. Chiba, T. Iwao, T. Matsunaga, Application of a
human intestinal epithelial cell monolayer to the prediction of oral drug absorp-
tion in humans as a superior alternative to the caco-2 cell monolayer, J. Pharm.
Sci. 105 (2016) 915–924.
[239] N. Navabi, M.A. McGuckin, S.K. Lindén, Gastrointestinal cell lines form polarized
epithelia with an adherent mucus layer when cultured in semi-wet interfaces
with mechanical stimulation, PLoS One 8 (2013), e68761.
[240] S.H. Kim, M. Chi, B. Yi, S.H. Kim, S. Oh, Y. Kim, S. Park, J.H. Sung, Three-dimensional
intestinal villi epithelium enhances protection of human intestinal cells from bac-
terial infection by inducing mucin expression, Integr. Biol. 6 (2014) 1122–1131.
[241] S.N. Bhatia, D.E. Ingber, Microﬂuidic organs-on-chips, Nature 201 (2014) 4.
[242] H.J. Kim, D.E. Ingber, Gut-on-a-Chip microenvironment induces human intestinal
cells to undergo villus differentiation, Integr. Biol. 5 (2013) 1130–1140.
[243] H.J. Kim, D. Huh, G. Hamilton, D.E. Ingber, Human gut-on-a-chip inhabited by mi-
crobial ﬂora that experiences intestinal peristalsis-like motions and ﬂow, Lab Chip
12 (2012) 2165–2174.[244] P.B. Persson, Ussing's chamber origin, Acta Physiol. (2016).
[245] S.M. Kalman, H.H. Ussing, Active sodium uptake by the toad and its response to the
antidiuretic hormone, J. Gen. Physiol. 38 (1955) 361–370.
[246] C. Schmidt, C. Lautenschlaeger, E.-M. Collnot, M. Schumann, C. Bojarski, J.-D.
Schulzke, C.-M. Lehr, A. Stallmach, Nano-and microscaled particles for drug
targeting to inﬂamed intestinal mucosa—a ﬁrst in vivo study in human patients,
J. Control. Release 165 (2013) 139–145.
[247] C. Lautenschläger, C. Schmidt, C.-M. Lehr, D. Fischer, A. Stallmach, PEG-
functionalized microparticles selectively target inﬂamed mucosa in inﬂammatory
bowel disease, Eur. J. Pharm. Biopharm. 85 (2013) 578–586.
[248] M. Ng, T. Fleming, M. Robinson, B. Thomson, N. Graetz, C. Margono, E.C. Mullany, S.
Biryukov, C. Abbafati, S.F. Abera, Global, regional, and national prevalence of over-
weight and obesity in children and adults during 1980–2013: a systematic analysis
for the Global Burden of Disease Study 2013, Lancet 384 (2014) 766–781.
[249] T.F. Teixeira, M.C. Collado, C.L. Ferreira, J. Bressan, Mdo C. Peluzio, Potential mech-
anisms for the emerging link between obesity and increased intestinal permeabil-
ity, Nutr. Res. 32 (2012) 637–647.
[250] S. Ding, P.K. Lund, Role of intestinal inﬂammation as an early event in obesity and
insulin resistance, Curr. Opin. Clin. Nutr. Metab. Care 14 (2011) 328.
[251] H.E. Raybould, Gut microbiota, epithelial function and derangements in obesity,
J. Physiol. 590 (2012) 441–446.
[252] E. Lau, C. Marques, D. Pestana, M. Santoalha, D. Carvalho, P. Freitas, C. Calhau, The
role of I-FABP as a biomarker of intestinal barrier dysfunction driven by gut micro-
biota changes in obesity, Nutr. Metab. 13 (2016) 1.
[253] C. Kless, V.M. Müller, V.L. Schüppel, M. Lichtenegger, M. Rychlik, H. Daniel, M.
Klingenspor, D. Haller, Diet-induced obesity causes metabolic impairment inde-
pendent of alterations in gut barrier integrity, Mol. Nutr. Food Res. 59 (2015)
968–978.
[254] A. Farhadi, S. Gundlapalli, M. Shaikh, C. Frantzides, L. Harrell, M.M. Kwasny, A.
Keshavarzian, Susceptibility to gut leakiness: a possible mechanism for
endotoxaemia in non-alcoholic steatohepatitis, Liver Int. 28 (2008) 1026–1033.
[255] Å. Sjöberg, M. Lutz, C. Tannergren, C. Wingolf, A. Borde, A.-L. Ungell, Comprehen-
sive study on regional human intestinal permeability and prediction of fraction
absorbed of drugs using the Ussing chamber technique, Eur. J. Pharm. Sci. 48
(2013) 166–180.
[256] A.H. Gitter, M. Fromm, J.-D. Schulzke, Impedance analysis for the determination of
epithelial and subepithelial resistance in intestinal tissues, J. Biochem. Biophys.
Methods 37 (1998) 35–46.
[257] L.L. Clarke, A guide to Ussing chamber studies of mouse intestine, Am. J. Physiol.
Gastrointest. Liver Physiol. 296 (2009) G1151–G1166.
[258] J. Reis, A. Dezani, T. Pereira, A. Avdeef, C. Serra, Lamivudine permeability study: a
comparison between PAMPA, ex vivo and in situ Single-Pass Intestinal Perfusion
(SPIP) in rat jejunum, Eur. J. Pharm. Sci. 48 (2013) 781–789.
[259] B. McNamara, D.C. Winter, J.E. Cuffe, G.C. O'Sullivan, B.J. Harvey, Basolateral K+
channel involvement in forskolin-activated chloride secretion in human colon,
J. Physiol. 519 (1999) 251–260.
[260] N.G. Schipper, K.M. Vårum, P. Stenberg, G. Ocklind, H. Lennernäs, P. Artursson,
Chitosans as absorption enhancers of poorly absorbable drugs: 3: inﬂuence of
mucus on absorption enhancement, Eur. J. Pharm. Sci. 8 (1999) 335–343.
[261] L.-A.B. Rawlinson, P.J. O'Brien, D.J. Brayden, High content analysis of cytotoxic
effects of pDMAEMA on human intestinal epithelial and monocyte cultures, J. Con-
trol. Release 146 (2010) 84–92.
[262] D.J. Brayden, S.-A. Cryan, K.A. Dawson, P.J. O'Brien, J.C. Simpson, High-content anal-
ysis for drug delivery and nanoparticle applications, Drug Discov. Today 20 (2015)
942–957.
[263] E.G. van de Kerkhof, A.-L.B. Ungell, Å.K. Sjöberg, M.H. de Jager, C. Hilgendorf, I.A. de
Graaf, G.M. Groothuis, Innovative methods to study human intestinal drug metab-
olism in vitro: precision-cut slices compared with ussing chamber preparations,
Drug Metab. Dispos. 34 (2006) 1893–1902.
[264] V. Rozehnal, D. Nakai, U. Hoepner, T. Fischer, E. Kamiyama, M. Takahashi, S. Yasuda,
J. Mueller, Human small intestinal and colonic tissue mounted in the Ussing cham-
ber as a tool for characterizing the intestinal absorption of drugs, Eur. J. Pharm. Sci.
46 (2012) 367–373.
[265] P.J. Hornby, P.R. Cooper, C. Kliwinski, E. Ragwan, J.R. Mabus, B. Harman, S.
Thompson, A.L. Kauffman, Z. Yan, S.H. Tam, Human and non-human primate intes-
tinal FcRn expression and immunoglobulin G transcytosis, Pharm. Res. 31 (2014)
908–922.
[266] P. Calleja, S. Espuelas, C. Vauthier, G. Ponchel, J.M. Irache, Controlled release, intes-
tinal transport, and oral bioavailablity of paclitaxel can be considerably increased
using suitably tailored pegylated poly (anhydride) nanoparticles, J. Pharm. Sci.
104 (2015) 2877–2886.
[267] J. Chen, C. Liu, W. Shan, Z. Xiao, H. Guo, Y. Huang, Enhanced stability of oral insulin
in targeted peptide ligand trimethyl chitosan nanoparticles against trypsin,
J. Microencapsul. 32 (2015) 632–641.
[268] T. Fan, C. Chen, H. Guo, J. Xu, J. Zhang, X. Zhu, Y. Yang, Z. Zhou, L. Li, Y. Huang,
Design and evaluation of solid lipid nanoparticles modiﬁed with peptide ligand
for oral delivery of protein drugs, Eur. J. Pharm. Biopharm. 88 (2014) 518–528.
[269] H. Lennernäs, Ö. Ahrenstedt, R. Hällgren, L. Knutson, M. Ryde, L.K. Paalzow, Region-
al jejunal perfusion, a new in vivo approach to study oral drug absorption in man,
Pharm. Res. 9 (1992) 1243–1251.
